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ABSTRACT 
 
 
Clostridium difficile is a major cause of infectious diarrhea in hospitals 
worldwide. Recurrent infections and an increase in antibiotic-resistant strains 
have made treatment of C. difficile infections extremely difficult. Although the 
clostridial cell surface is recognized to play an important role in clostridial 
pathogenesis, biological functions of few cell surface proteins are known. Also, 
apart from the toxins, proteins released by C. difficile are poorly studied. 
In order to comprehensively identify proteins secreted by C. difficile (either 
exposed on the surface or released in the extracellular environment) we tried two 
different proteomic approaches. Characterization of the bacterial surface can be 
done applying a „surfome‟ analysis, which involves surface proteolysis of intact 
cells and identification of released peptides by mass spectrometry; the released 
proteins can instead be identified by performing similar analysis on bacterial 
culture supernatants. While the surface digestion approach was not successful 
because of bacterial lysis during sample preparation, analysis of culture media 
led to the identification of several proteins. We analyzed bacterial culture 
supernatants prepared from two clinical isolates, 630 and R20291. Interestingly, 
majority of the proteins identified were putative surface-associated proteins. 
These could be largely classified into proteins associated to the peptydoglycan 
(CWPs and LPXTG-anchored), extracellular hydrolases, transporters and 
flagellar proteins. Several proteins of unknown function were also identified. 
Among them, we selected for further characterization two proteins potentially 
involved in C. difficile pathogenesis. 
CD630_28300, a protein of unknown function, shares sequence similarity with 
the anthrax lethal factor, a known zinc-metallopeptidase. We demonstrated that 
the recombinant protein binds divalent cations and is able to cleave fibronectin in 
a zinc-dependent manner in vitro and on human fibroblasts. Therefore we named 
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this novel zinc-metalloprotease Zmp1. Using mutants of Zmp1, we identified 
residues important in zinc binding and enzymatic activity.  
CD630_36690, a protein with similarity to a sporulation and germination factor 
of Bacillus subtilis, was also identified in the proteomic screen. It is a small 
protein expressed on the surface of vegetative cells of C. difficile strain 630. An 
isogenic mutant lacking CD630_36690 demonstrated a phenotype suggesting a 
role in sporulation or germination.  
Employing a combination of proteomic and molecular approaches we have 
discovered novel extracellular factors that may be important in key steps of 
clostridial pathogenesis. 
 
 
1 
 
INTRODUCTION 
 
 
1. Clostridium difficile 
Clostridium difficile is a Gram-positive, spore-forming obligate anaerobe, 
belonging to the phylum Firmicutes. It is an intestinal pathogen of humans and 
animals and is recognized as the most common cause of nosocomial diarrhea 
(Poxton et al., 2001; Rupnik et al., 2009; Kuipers and Surawicz, 2008). C. 
difficile was first described in 1935 as part of the intestinal microflora in 
neonates. Although the severe form of C. difficile disease, pseudomembranous 
colitis, was first reported in 1893, it was not identified as the causative agent of 
human disease until 1978 (Bartlett, 1994). As for other Firmicutes (Bacilli and 
Clostridia), C. difficile can exist in two forms: the vegetative cell and the spore 
(Fritze, 2004) (Fig. 1). The vegetative cell is the metabolically active and 
toxigenic form, while the spore, metabolically dormant, is able to survive for 
long periods and is resistant to harsh physical or chemical treatments (Setlow, 
2007). The spore is the transmissible form of the disease, contributes to survival 
of the organism in the host and is responsible for recurrence of disease (Lawley 
et al., 2009; Vedantam et al., 2012). 
 
 
Figure 1. C. difficile spore and vegetative cell. From Vedantam et al., 2012. 
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2. C. difficile associated disease (CDAD) 
Upon ingestion of spores that are present in the air or on contaminated 
material, C. difficile can reach the gut. Presence in the gut can be asymptomatic 
(1–3% of healthy adults and 40–60% of neonates) or can produce a range of 
symptoms generally known as Clostridium difficile associated disease (CDAD). 
These symptoms usually appear in the presence of risk factors, such as prolonged 
antibiotic therapy, advanced age or hospitalization (Poxton et al., 2001; Rupnik 
et al., 2009; Kuipers and Surawicz, 2008).  
Mild cases may present with slight fever, loose stools and abdominal cramps. 
The disease can progress to severe colitis with typical adherent 
pseudomembranes, which can coalesce to obscure the mucosa. Severe colitis can 
result in toxic megacolon, colon perforation and progressive multiorgan failure. 
Mortality in patients with CDAD ranges from 3–30% (Poxton et al., 2001). 
C. difficile is recognized as the main cause of infectious diarrhea that develops in 
patients after hospitalization and antibiotic treatment (Rupnik et al., 2009) (Fig. 
2). The association between antimicrobial therapy and CDAD has been almost 
universal, as C. difficile can only colonize the gut if the normal intestinal 
microbiota is disturbed or absent. Sequencing of the genome of the C. difficile 
strain 630, in 2006, showed that a large proportion (11%) of the genome consists 
of mobile genetic elements, mainly in the form of conjugative transposons. These 
mobile elements are putatively responsible for the acquisition by C. difficile of an 
extensive array of genes involved in antimicrobial resistance (Sebaihia et al., 
2006). Antibiotic treatment is always the leading risk for CDAD in people and 
animals. Initial studies focused on clindamycin and cephalosporins (Aronsson et 
al., 1985; Gerding, 2009). Then, fluoroquinolones emerged as major inducing 
agents and were implicated in several outbreaks that could be controlled only by 
restraining or prohibiting use of the entire class (Gerding, 2004; Kallen et al., 
2009). Resistance to the antibiotics that are currently used to treat CDAD 
(metronidazole and vancomycin) has thus far not posed a significant threat.  
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Advanced age is a risk, with most reports showing sharp increases in incidence in 
persons over 65 years and a direct correlation with age above that threshold 
(Aronsson et al., 1985; Pépin et al., 2004). Another important risk is contact with 
the healthcare system, which is heavily contaminated by C. difficile (Best et al., 
2010; Cohen et al., 2010; Donskey, 2010; Freeman et al., 2010). Also, there is 
increasing evidence that proton pump inhibitors promote CDAD (Leonard et al., 
2007; Linsky et al., 2010). 
Patients in the community are also at risk for CDAD, albeit at a considerably 
lower rate than those who are hospitalized. Community-associated CDAD 
without previous direct or indirect contact with a hospital environment remains 
rare compared with hospital-acquired CDAD. Nevertheless, it has been reported 
in populations that were previously thought to be at low risk, such as young 
individuals and pregnant women (Rupnik et al., 2009). Possible community 
sources for CDAD include soil, water, pets, animals used for food, meats and 
vegetables (al Saif et al., 1996). 
In animals, C. difficile was mainly known as an important pathogen in horses, 
although it has been reported to infect numerous wild and domestic animals 
(Rupnik, 2007). As with infection of humans, disease in animals is associated 
with non-protective normal gut flora (Songer and Anderson, 2006; Keel and 
Songer, 2006; Rodriguez-Palacios et al., 2006). 
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Figure 2. The effect of antibiotics on the normal gut flora and the risk of Clostridium difficile 
associated disease (CDAD). Patients are resistant to CDAD if their normal gut flora is not disrupted by 
antibiotics (a). Once antibiotic treatment starts, infection with a C. difficile strain that is resistant to the 
antibiotic is more likely while the antibiotic is being administered, owing to the presence of the antibiotic 
in the gut (b). When the antibiotic treatment stops, the levels of the antibiotic in the gut diminish rapidly, 
but the microflora remains disturbed for a variable period of time (indicated by the break in the graph), 
depending on the antibiotic given. During this time, patients can be infected with either resistant or 
susceptible C. difficile (c). Finally, after the microflora recovers, colonization resistance to C. difficile is 
restored (d). From Rupnik et al., 2009. 
 
 
 
2.1. Therapy 
Two of the most difficult challenges for CDAD treatment are the management of 
multiple recurrences and the management of fulminant or severe complicated 
CDAD. Patients with multiple recurrences of CDAD typically respond to 
treatment with vancomycin or metronidazole, but then diarrhea symptoms 
resume within days to weeks after treatment is stopped. Between 20% and 50% 
of these recurrences are caused by new C. difficile organisms, indicating 
reinfection rather than a relapse of the original infection (Johnson et al., 1989; 
O‟Neill et al., 1991). No highly effective means to treat these multiple 
recurrences have been devised, and most are treated with prolonged pulse dosing 
of vancomycin in the hope of keeping C. difficile from regrowing while the 
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normal flora recovers. The most effective treatment for these patients has been 
replenishment of the normal bacterial flora with a faecal transplant delivered 
either by nasogastric tube or by enema (Aas et al., 2003). No highly effective 
treatment has been found for severe complicated CDAD, and in some cases 
surgical removal of the colon can be the only remaining life-saving measure 
(Lamontagne et al., 2007). Newer agents for treatment of multiple relapsing and 
fulminant CDAD are needed, and several approaches are under investigation, 
including vaccines, toxin-binding agents and passive antibodies. 
 
2.2. Emergence of hypervirulent strains 
Since 2000, there has been a dramatic increase in rates and severity of CDAD 
noted in North America and much of Europe. The first reports were from Canada 
in 2003, showing a fourfold increase in CDAD rates, and included reviews 
showing fluoroquinolones as the dominant inducing agents and 10-fold-higher 
rates in persons over 65 years. Similar studies in the United States showed an 
increase in CDAD rate and mortality (Dubberke et al., 2010; Redelings et al., 
2007; Ricciardi et al., 2007). European data also showed increased CDAD rates 
and multiple hospital-associated outbreaks (Freeman et al., 2010). 
The increasing incidence and severity of CDAD in North America and much of 
Europe has been attributed to the emergence of hypervirulent ribotype 027 
(McDonald et al., 2005; Loo et al., 2005; O‟Connor et al., 2009; Warny et al., 
2005). The factor thought to contribute to incidence is the strain's resistance to 
fluoroquinolones, and enhanced virulence may reflect increased toxin production 
in vitro (Warny et al., 2005). In addition, emerging strains belonging to PCR-
ribotype 017 and 078, that are also associated with severe disease, have been 
isolated in parts of Asia and Europe (Drudy et al., 2007; Kim et al., 2008). There 
is currently a widespread interest in understanding the underlying factors that 
have led to the emergence of these hypervirulent C. difficile strains. 
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3. C. difficile infection 
Upon contact with contaminated surfaces, C. difficile spores and vegetative 
cells can be ingested. Spores, which are able to survive the acid environment of 
the stomach, can reach the small intestine. Here they germinate in response to 
specific germination-promoting factors, resulting in a vegetative morphotype 
(Fig. 3). In susceptible hosts, this vegetative form will proliferate in the colon, 
producing toxins (if the strain is toxigenic) and resulting in the characteristic 
pathology (Vedantam et al., 2012). 
During CDAD, C. difficile vegetative cells initiate the process of sporulation 
(Fig. 3). Spores are responsible for transmission of the disease. Patients with 
CDAD episodes enter a highly contagious super-shedder state, excreting high 
levels of infectious spores to the environment. These spores are resistant to most 
conventional disinfection methods and can survive for long periods (Lawley et 
al., 2009). Also, spores are responsible for recurrencies of CDAD. A fraction of 
spores remains adhered to the intestinal surface. These spores, which are not 
affected by antibiotic therapies commonly used for CDAD, then germinate, 
outgrow and recolonize the host gastrointestinal tract, causing relapse of disease 
(Sarker and Paredes-Sabja, 2012). 
 
 
 
Figure 3. Schematic of human C. difficile infection. Modified from Vedantam et al., 2012. 
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4. C. difficile virulence factors 
Toxins are the most well studied virulence factors of C. difficile, as only 
toxigenic strains have been so far associated to disease (Kuehne et al., 2010; 
Lyras et al., 2009; Voth and Ballard, 2005; Schwan et al., 2009). C. difficile 
produces two main toxins, toxin A and toxin B (Voth and Ballard, 2005), which 
account for symptoms of disease and produce intestinal damage, ensuring the 
release of nutrients from the damaged colonic epithelium. However, other factors 
must play a role in processes such as adaptation to the host‟s colonic 
environment, adhesion to the gut mucosa, colonization and dissemination of the 
infection.  
Efforts to elucidate C. difficile pathogenic mechanisms have been hampered for 
many years by a lack of molecular tools (Kuehne et al., 2011). In recent years, 
the sequencing of several C. difficile genomes (Sebaihia et al., 2006; He et al., 
2013) and the spread of molecular tools that allow C. difficile genetic studies 
(Cartman et al., 2012; Kuehne et al., 2011) have led to a great wealth of 
knowledge regarding the molecular basis of C. difficile pathogenesis and 
nontoxin virulence factors likely involved in the early stages of CDAD. Still, 
very little is known about factors other than toxins involved in pathogenesis. 
Bacterial adherence has been reported to play a role in C. difficile pathogenic 
strategy. It is clearly established that C. difficile can associate with intestinal 
mucosa in humans and hamsters (Borriello et al., 1988). Also, there appears to be 
a positive correlation between virulence and mucosal adherence in vivo 
(Borriello et al., 1988). Early studies of interactions between C. difficile 
vegetative cells and intestinal enterocyte cells demonstrated that C. difficile cells 
adhere to the microvilli of the apical surfaces of Caco-2 cells (Eveillard et al., 
1993; Cerquetti et al., 2002). A recent study demonstrated that during infection 
of intestinal enterocyte-like Caco-2 cells, C. difficile differentially expressed 
approximately 7% of its genome, resulting in the upregulation of numerous 
putative auxiliary virulence factors (Janvilisri et al., 2010).  
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Several surface factors involved in adhesion and colonization have been 
identified and partially characterized in the last years through in vitro or in vivo 
studies: most relevant are SLPs (Calabi et al., 2002a), Cwp66 (Waligora et al., 
2001), Fbp68 (Barketi-Klai et al., 2011), Cwp84 (Janoir et al., 2007) and flagella 
(Dingle et al., 2011; Tasteyre et al., 2001a). Also, it is likely that during 
colonization of the gut C. difficile releases not only the known toxins but also 
other proteins. However, there is little information about proteins secreted by C. 
difficile into its environment. A recent report described Srl, a protein found in 
culture supernatants which modulates the cell sensitivity to toxins A and B 
(Miura et al., 2011). Other factors which have been proposed to be involved in 
colonization are proteolytic enzymes (Poilane et al., 2008) and capsule (Davies 
and Borriello, 1990), but these have been so far poorly characterized. 
It is well known that formation of biofilms influences the ability of several 
pathogens to colonize and establish an infection (Nobbs et al., 2009; Allsopp et 
al., 2010), also providing an enclosed environment to escape immune responses 
and resist to antibiotics (Beloin et al., 2008; Mah and O‟Toole, 2001). 
Interestingly, C. difficile has been recently shown to form biofilms in vitro, an 
ability which could be crucial for clostridial colonization and persistence in the 
host (Dapa et al., 2012; Dawson et al., 2012).  
 
4.1. Toxins 
4.1.1. Toxin A and toxin B 
The main virulence factors of C. difficile have been identified as toxins A and 
B, which target the Ras superfamily of GTPases for modification via 
glycosylation, ultimately leading to destruction of intestinal epithelial cells 
(Carter et al., 2012; Voth and Ballard, 2005).  
Toxin A and toxin B are encoded in the Pathogenicity Locus (PaLoc) (Fig. 4a). 
The PaLoc of C. difficile is approximately 19.6 kb in size and is stable and 
conserved in toxigenic strains (Cohen et al., 2000; Voth and Ballard, 2005). 
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Nontoxigenic strains lack the PaLoc; however, isolates with a defective PaLoc 
can still cause disease (Cohen et al., 2000; Curry et al., 2007). Five genes are 
present on the PaLoc: tcdA, tcdB, tcdC, tcdE and tcdR. The two toxin genes, tcdA 
and tcdB, are closely aligned, separated by an intervening sequence (tcdE) (Voth 
and Ballard, 2005). tcdE encodes a holin, a protein whose pore-forming activity 
has been proposed to allow the release of TcdA and TcdB from the cell, although 
it has recently been shown that it does not exhibit pore-forming function in C. 
difficile (Olling et al., 2012; Voth and Ballard, 2005). tcdR, found upstream of 
tcdB, is a major positive regulator of tcdA and tcdB expression, responsive to 
environmental conditions and increased during stationary phase (Voth and 
Ballard, 2005). tcdC, found downstream of tcdA, has been considered for long 
time a negative regulator of toxin production, but it has recently been shown that 
functionality of this gene does not affect toxin production (Cartman et al., 2012; 
Carter et al., 2012).  
All the genes of the locus except tcdC are expressed during stationary phase. 
Dineen and co-workers have shown that toxin gene expression is also regulated 
by the global gene regulator CodY, which acts by monitoring environmental 
nutrient factors. The authors demonstrated that in the presence of sufficient 
nutrients CodY binds to the promoter region of tcdR and represses toxin gene 
expression. When nutrients in the environment are lacking, toxin gene expression 
is derepressed (Voth and Ballard, 2005; Carter et al., 2012; Dineen et al., 2007).  
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Figure 4. Toxins produced by C. difficile. (a) Two large toxins, toxin A and toxin B (TcdA and TcdB), 
are encoded on the pathogenicity locus (PaLoc), which comprises five genes. Both toxins are single-chain 
proteins, and several functional domains and motifs have been identified. TcdB is shown in detail below 
the PaLoc. (b) A third toxin, the binary toxin or CDT (C. difficile transferase), is encoded on a separate 
region of the chromosome (CdtLoc) and comprises three genes. The binary toxin is composed of two 
unlinked proteins, CdtB and CdtA. CdtB has a binding function and CdtA is the enzymatic component. 
From Carroll and Bartlett, 2011. 
 
 
TcdA and TcdB are part of the large clostridial toxin family along with 
Clostridium sordellii lethal toxin and hemorrhagic toxin and Clostridium novyi 
alpha toxin (Carter et al., 2012). Both toxins are glucosyltransferases. They 
transfer a UDP-glucose to small GTPases, such as Rho, Rac, and Cdc42, in the 
cell. These small proteins are important in regulating signaling pathways. 
Glycosylation disrupts these pathways, which results in morphological changes, 
inhibition of cell division and membrane trafficking, and eventual cell death 
(Dawson et al., 2009; Voth and Ballard, 2005). 
TcdA binds to the apical side of the cell and, after internalization, causes 
cytoskeletal changes that result in disruption of tight junctions and loosening of 
the epithelial barrier, in cell death or in the production of inflammatory mediators 
that attract neutrophils. Disruption of tight junctions enables both TcdA and 
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TcdB to cross the epithelium. TcdB binds preferentially to the basolateral cell 
membrane. Both toxins are cytotoxic and induce the release of various 
immunomodulatory mediators from epithelial cells, phagocytes and mast cells, 
resulting in inflammation and the accumulation of neutrophils (Rupnik et al., 
2009) (Fig. 5). 
TcdA (308 kDa), an enterotoxin, was originally believed to be the toxin 
associated with disease, and therefore necessary for virulence, until TcdA−, 
TcdB+ strains were associated with outbreaks of severe C. difficile infection 
(Freeman et al., 2010). TcdB (270 kDa), a cytotoxin, is 100- to 1000-fold more 
toxic to culture cells than TcdA is. Lyras and co-workers reported that TcdB, not 
TcdA, is essential for virulence (Lyras et al., 2009). However, a paper by Kuehne 
and co-workers refutes the assertion that only toxin B is essential for virulence 
and re-establishes the observation that both toxins can cause significant disease 
(Kuehne et al., 2009). In that study, TcdA+, TcdB− isolates were as likely to 
cause disease as the wild-type strains. 
 
 
 
Figure 5. Clostridium difficile pathogenesis. C. difficile colonizes the intestine (colon) after disruption 
of the normal intestinal flora. In the schematic, bacterial cells are shown as free cells and attached to host 
cells. TcdA binds to the apical side of the cell and, after internalization, causes cytoskeletal changes that 
result in disruption of tight junctions and loosening of the epithelial barrier, in cell death or in the 
production of inflammatory mediators that attract neutrophils. Disruption of tight junctions enables both 
TcdA and TcdB to cross the epithelium. TcdB binds preferentially to the basolateral cell membrane. Both 
toxins are cytotoxic and induce the release of various immunomodulatory mediators from epithelial cells, 
phagocytes and mast cells, resulting in inflammation and the accumulation of neutrophils. From Rupnik 
et al., 2009. 
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Both toxins are large single-stranded proteins, and recent X-ray crystallography 
and small angle X-ray scattering models (SAXS) of TcdB suggest four structural 
domains (Albesa-Jove et al., 2010) (Fig. 4a). These domains include (a) a 
biologically active N-terminal glucosyltransferase protruding from the core of the 
protein; (b) a cysteine protease domain; (c) a middle translocation section that 
contains a hydrophobic region implicated in toxin delivery; and (d) a C-terminal 
receptor-binding domain (Albesa-Jove et al., 2010). Toxin activity is located in 
the N-terminal domain. This portion is delivered into the cytosol of host cells 
(Jank and Aktories, 2008). Cleavage of the biologically active segment occurs by 
autoproteolysis via the cysteine protease domain (Albesa-Jove et al., 2010). The 
C-terminal domain has short combined repetitive oligopeptides (CROPs) for 
receptor binding. In animal models of TcdA, carbohydrate structures play a role 
in toxin binding (Rupnik et al., 2009; Voth and Ballard, 2005). These 
carbohydrates are not present in humans and the glycoprotein gp96 present in the 
human colon is the receptor for TcdA (Rupnik et al., 2009). 
Once inside the cell, the toxins target the Ras superfamily of small GTPases 
(Rho, Rac, and Cdc) (Dineen et al., 2007), modifying them through glycosylation 
(Voth and Ballard, 2005). Glycosylation prevents the structural changes required 
for active conformation of these GTPases, significantly altering their function. 
Cells shrink and become rounded owing to disaggregation of the actin 
cytoskeleton, eventually dying (Schirmer and Aktories, 2004; Voth and Ballard, 
2005). Tight junctions between epithelial cells are disrupted. This allows 
neutrophils to migrate to the intestines, contributing to the inflammatory 
response, typical of colitis (Voth and Ballard, 2005). Biological inactivation of 
the GTPases results in serious physiological consequences, such as inhibition of 
secretion, transcriptional regulation, and eventual apoptosis (Schirmer and 
Aktories, 2004; Voth and Ballard, 2005). In addition to direct cytotoxic effects, 
TcdA stimulates release of tumor necrosis factor from activated macrophages as 
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well as cytokine production. These activities cause fluid accumulation and 
further the inflammatory responses (Voth and Ballard, 2005). 
 
4.1.2. C. difficile Transferase (Binary toxin CDT) 
While the role of the toxins TcdA and TcdB in disease is well documented, 
the role of the binary toxin is less certain. 
C. difficile transferase (CDT), also known as binary toxin, is encoded by the Cdt 
locus (CdtLoc) (Fig. 4b). It is found in approximately 6%–12.5% of strains 
overall (Schwan et al., 2009; Sundriyal et al., 2010). CDT is an ADP-
ribosylating toxin that disrupts the cytoskeleton of the cell, leading to excessive 
fluid loss, rounding of the cell, and eventual cell death (Sundriyal et al., 2010). 
CDT is composed of two subunits, CDTa and CDTb (Fig. 4b). Each component 
alone is not cytotoxic, while together they cause cytotoxicity in vitro. The fact 
that the incidence of CDT is higher in some of the epidemic strains suggests that 
it contributes to the severity of disease (Sundriyal et al., 2010; Geric et al., 2006).  
Findings by Schwan and co-workers (Schwan et al., 2009) revealed that CDT 
induces the formation of novel thin, dynamic, microtubules on the surface of 
epithelial cells, leading to increased adherence of bacteria in vitro and in vivo. 
Electron microscopy showed that these protrusions increase adherence to the 
epithelial cell surface by approximately fivefold in vitro and fourfold in the 
mouse large intestine, thereby possibly playing an important role in intestinal 
colonization (Schwan et al., 2009). 
 
4.2. Surface virulence factors 
S-layer proteins 
Many prokaryotes have a surface-associated crystalline or paracrystalline 
array, formed by identical subunits of glycoproteins or proteins, typically named 
surface-layer (S-layer) (Sara and Sleytr, 2000). Several functions have been 
proposed for bacterial S-layers, including acting as molecular sieves, protective 
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factors against parasitic attack, virulence factors and adhesion sites for 
extracellular proteins (Sara and Sleytr, 2000). C. difficile has two superimposed 
and structurally different S-layer lattices, a high-molecular-weight (HMW) SLP 
( 40 kDa) and a low-molecular-weight (LMW) SLP ( 35 kDa) (Cerquetti et al., 
2000; Calabi et al., 2001; Karjalainen et al., 2001) (Fig. 6a). 
A single gene, slpA, encodes both proteins produced through post-translational 
cleavage of a common precursor, with the N-terminal portion coding for the 
LMW SLP and the C-terminal portion coding for the HMW SLP (Calabi et al., 
2001). The translated gene product undergoes two rounds of post-translational 
cleavage, firstly to remove the signal sequence following secretion, and then 
internally to release the two mature SLPs (Fig. 6b). 
Both HMW and LMW are tightly linked by a noncovalent complex (Fagan et al., 
2009). Interestingly, while the HMW SLP is localized in the internal surface of 
the bacteria and is immunologically conserved, the LMW SLP localizes to the 
external surface of the bacterium and is immunologically variable (Cerquetti et 
al., 2000; Takeoka et al., 1991; Fagan et al., 2009), suggesting some role of 
LMW in evasion of the immune system (Vedantam et al., 2012).  
SLPs play a role in adhesion. Initial studies on the SLPs‟ adhesive properties 
demonstrated that removal of the SLPs through chemical treatments or treatment 
of C. difficile bacterial cells with anti-SLP antibodies abolished adherence of C. 
difficile to mouse 929 and human HeLa cells (Takeoka et al., 1991). Later studies 
demonstrated that purified SLPs bind to intestinal tissues and several proteins of 
the extracellular matrix (Calabi et al., 2002a), yet to date the precise host 
receptor has not been identified. 
Besides the aforementioned slpA, C. difficile 630 genome contains 28 paralogs of 
the HMW SLP, which are known as the family of cell wall proteins (CWPs) 
(Sebaihia et al., 2006). All of the members of the C. difficile CWP family contain 
up to three copies of the cell wall-binding motif (PF01422), a motif characteristic 
of the SLPs which is involved in anchoring the protein to the outer surface of the 
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bacterium, as well as a variable motif that might be function-specific (Sebaihia et 
al., 2006). All the paralogs contain a signal sequence and are predicted to be 
surface localized; indeed, several have been detected experimentally
 
(Wright et 
al., 2005). Among these, some have been partially characterized and for them a 
role has been proposed in host cell adherence or other pathogenic processes.  
Of the 29 paralogs identified so far, 12 map in a densely arranged cluster 
surrounding slpA and are all transcribed in the same direction, suggesting the 
possibility of coordinated regulation and related functions (Calabi et al, 2002a 
Karjalainen et al, 2001; Calabi et al, 2002b).  
Despite the wealth of knowledge on a few CWPs, the lack of information on the 
remaining CWP paralogs hinders our ability to fully understand the role of these 
cell surface proteins in the pathogenesis of C. difficile and their importance for 
early colonization or evasion of the host‟s immune system. Indeed, evidence 
from microarray suggests that C. difficile remodels its cell surface during early 
contact with Caco-2 cells (Janvilisri et al., 2010). These changes include the 
upregulation of several genes that encode putative auxiliary virulence factors, 
indicating that C. difficile remodels its envelope perhaps to enhance exposure of 
virulence attributes relevant for colonization, spread and/or early invasion stages 
(Janvilisri et al., 2010).  
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Figure 6. Model of the cell wall of Clostridium difficile. (A) The two SLPs are shown above the 
peptidoglycan layer: the HMW SLP (green) and the LMW SLP (red). Other minor cell wall proteins are 
shown as two-lobed structures (blue and orange). Putative cell wall polymers, including putative lipid-
containing polymers,  are shown as vertical brown bars. (B) The precursor protein SlpA, showing the 
cleavage sites generating the signal peptide and the mature HMW SLP and LMW SLP. Modified from 
Fagan et al., 2009. 
 
 
Cwp84 and Cwp13 
During early colonization of host surfaces, in several bacterial species (i.e., 
Streptococcus pyogenes and Pseudomonas aeruginosa) proteolytic enzymes play 
an important role in degrading host proteins, contributing to nutrient acquisition, 
or in the processing of bacterial proteins involved in virulence (Maeda, 1996; 
Matsumoto, 2004).  
The Cwp84 protease, conserved in various C. difficile strains (Savariau-
Lacomme et al., 2003) and localized in the locus containing the slpA gene, was 
detected by CDAD patient‟s antisera, suggesting a potential role of Cwp84 in 
pathogenesis of CDAD (Péchiné et al., 2005a). Cwp84 is a cysteine protease, 
likely synthesized as an inactive proprotein of 80 kDa, that autoprocesses itself to 
a 47-kDa mature Cwp84 (Janoir et al., 2007; Chapetonmontes et al., 2011). 
Using both chemical and genetic techniques, the cysteine protease Cwp84 was 
shown to mediate cleavage of the mature SlpA precursor (Kirby et al., 2009; 
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Dang et al., 2010). In a C. difficile cwp84 mutant strain, SlpA weakly binds to 
the bacteria‟s cell wall primarily due to the lack of formation of the mature 
subunits, which might explain the slower growth of a C. difficile cwp84 strain 
when compared with parental strain (Kirby et al., 2009). Neither chemical 
inhibition of Cwp84 (Dang et al., 2010) nor inactivation of the cwp84 gene 
(Kirby et al., 2009) resulted in lethality, though severe growth defects were seen 
in both cases. The presence of uncleaved SlpA in the cell wall of the cwp84 
mutant resulted in aberrant retention of other cell wall proteins, suche as Cwp66 
and Cwp2, at the cell surface and subsequent release in the culture supernatant 
(de la Riva et al., 2011). These results indicate that correct processing of SlpA is 
important to retain healthy bacterial cells and suggest that perturbation of 
processing may affect the ability of bacteria to compete with other bacterial 
species in certain environments, for example, in the complex microbiota of the 
intestine. Despite these observations, C. difficile cwp84 mutants are competent in 
causing CDAD (Kirby et al., 2009). 
Cwp84 is also involved in degradation of fibronectin, vironectin and laminin 
presumably inducing a loss in the integrity of the host‟s colonic epithelium and 
an increase in toxin diffusion (Janoir et al., 2007). In recent years, Cwp84 has 
been considered as a potential target for chemical inhibitors (Dang et al., 2010; 
Tam Dang et al., 2012) and as a potential vaccine candidate (Sandolo et al., 
2011; Péchiné et al., 2011).  
Another putative cysteine protease, Cwp13, shares 63.2% amino acid identity to 
Cwp84, but plays an auxiliary role in the assembly of the S-layer (de la Riva et 
al., 2011). Cwp13 was shown to cleave SlpA in a different site respect to Cwp84, 
an activity that was suggested to reflect a role in cleavage and degradation of 
misfolded proteins at the cell surface. It was also shown to have a role in 
processing Cwp84, although it is not essential for Cwp84 activity (de la Riva et 
al., 2011). 
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Cwp66 
Cwp66 has a molecular size of 66 kDa and is anchored to the cell surface 
through its N-terminal domain (Waligora et al., 2001). Only the C-terminal of 
Cwp66 was detectable by immunoelectron microscopy after cells were subjected 
to a heat shock, suggesting that the N-terminal domain is embedded in the cell 
wall and is inaccessible to antibodies. Competitive inhibition assays showed that 
Cwp66 is an adhesin (Waligora et al., 2001).  However, given the fact that the C-
terminal domain could not be detected by immunoelectorn microscopy of non-
heat shock cells, the precise role of Cwp66 during in vivo adhesion in absence of 
heat shock remains unclear. 
 
CwpV 
CwpV has three cell wall anchoring motifs, a region of unknown function, 
and a C-terminal domain of variable number repeats (Emerson et al., 2009). 
CwpV is regulated by phase variation through DNA inversion by a site-specific 
recombinase and is expressed in approximately 5% of the cells under laboratory 
conditions (Emerson et al., 2009). Those cells expressing CwpV had no 
increment in adhesion to Caco-2 cells, but had the ability to autoaggregate 
forming denser and more randomly packed cellular organizations (Reynolds et 
al., 2011). Although repeats vary in size and are antigenically different between 
strains, CwpV exhibited conserved aggregation promoting function organizations 
(Reynolds et al., 2011). Autoaggregative proteins play a role in biofilm 
formation. Recently, C. difficile has been shown to form biofilms on abiotic 
substrates (Dapa et al., 2012; Dawson et al., 2012). Moreover, infected mice 
have been shown to have large aggregates of C. difficile cells in regions with 
severe inflammation (Lawley et al., 2009). These data suggest that CwpV might 
enhance C. difficile‟s ability to colonize colonic surfaces (Reynolds et al., 2011). 
Due to its presence in a small fraction of the population, it is likely that CwpV 
might play a role in antigenic variation, or alternatively, might allow evasion of 
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the innate immune system of a small fraction to cause further relapse episodes 
(Reynolds et al., 2011). 
 
GroEL 
Adherence to tissue culture cells was demonstrated to be augmented by 
various stresses, such as heat, osmotic and acid shock as well as iron 
insufficiency (Waligora et al., 1999). 
GroEL localizes at the cell surface, is predominantly membrane bound, and is 
released extracellularly after heat shock (Hennequin et al., 2001b). Treatment of 
C. difficile vegetative cells with polyclonal antibodies specific to C. difficile 
GroEL reduced their ability to adhere to Vero cells in culture (Hennequin et al., 
2001b). The C. difficile GroEL is upregulated during heat shock (Hennequin et 
al., 2001a), suggesting that it might play a role during clinically relevant heat 
stress as recently suggested (Jain et al., 2011). However, genetic studies will be 
required to determine the precise role of GroEL in CDAD. 
 
Flagella 
Flagella have been implicated in internalization of Campylobacter jejuni and 
Legionella pneumophila (Dietrich et al., 2001; Grant et al., 1993) and in 
adherence and colonization of C. jejuni (Mcsweegan et al., 1986) and 
Helicobacter pylori (Eaton et al., 1996). In C. difficile, nonflagellated strains 
showed a tenfold reduced adherence to tissue in the mouse cecum than 
flagellated strains belonging to the same serogroup, suggesting that the flagella 
might have some role in adherence (Tasteyre et al., 2001a; Tasteyre et al., 
2001b). Studies on sera from convalescent patients have shown that antibody 
responses against both FliC and FliD are generated, implicating them as 
important virulence factors during the course of CDAD (Péchiné et al., 2005a; 
Péchiné et al., 2005b). Genetic studies demonstrated that inactivation of either 
the flagellin (fliC) or flagellar cap (fliD) genes results in complete loss of flagella 
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as well as motility of C. difficile (Dingle et al., 2011). Strikingly, both C. difficile 
fliC and fliD mutant strains exhibited higher adherence to enterocyte-like Caco-2 
cells and more virulence in hamsters than the wild-type C. difficile strain delta-
ermB (Dingle et al., 2011). Indeed, when C. difficile vegetative cells enter in 
contact with Caco-2 cells, microarray and real-time PCR results suggest that 
there is a downregulation of the genes involved in flagellar assembly (i.e., fliH 
and flgG) (Janvilisri et al., 2010). These results suggest that in C. difficile the 
flagellum is adequately regulated to aid with motility when in the colonic lumen 
and with adherence when entering in contact with Caco-2 cells (Vedantam et al., 
2012). 
In accordance with this, Aubry and co-workers (Aubry et al., 2012) have recently 
demonstrated that the flagellar regulon of C. difficile modulates toxin production 
and that flagellar mutants have a corresponding change in virulence respect to the 
parental strain in a hamster model of C. difficile infection. 
 
Fbp68 
Extracellular matrix (ECM) components are required for multiple cellular 
functions during development, such as proliferation, migration, tissue-specific 
gene expression and, ultimately, apoptosis (Timpl and Brown, 1996). 
Surprisingly, several bacterial pathogens are able to use these proteins for 
adhesion through adhesins localized in the bacterial cell surface. This is also the 
case for C. difficile cells, which interact with several proteins of the ECM, such 
as fibrinogen, laminin, fibronectin and collagen I, III, IV and V (Cerquetti et al., 
2002), suggesting that C. difficile vegetative cell adhesins may take advantage of 
these molecules, using them as molecular bridges to increase adherence to the 
colonic epithelium. 
Fibronectin is a ubiquitous glycoprotein with a molecular size of 450 kDa found 
in the body fluids and ECM (Henderson et al., 2011). Fibronectin-binding 
proteins have been well described in Streptococci and Staphylococci, and act as 
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ligands for fibronectin increasing their ability to infect host cells (Van Der Flier 
et al., 1995; Navarre and Schneewind, 1999). Interestingly, a gene (fbp68) 
encoding a putative fibronectin binding protein has been found in all draft-
assembled and completed genomes of C. difficile sequenced to date (Vedantam et 
al., 2012). Indeed, C. difficile Fbp68 is able to bind to the ECM proteins 
fibronectin, fibrinogen and, to a lesser extent, to vitronectin (Hennequin et al., 
2003). A significant reduction in adherence to Vero cells was observed when C. 
difficile cells were pretreated with anti-Fbp68 antibody (Hennequin et al., 2003). 
In addition, C. difficile cells adhered to a lesser extent to Caco-2 cells pretreated 
with anti-Fbp68 antibody or in siRNA-transfected Caco-2 cells (Lin et al., 2011). 
C. difficile fbp68 cells had a slightly slower cecal colonization and intestinal 
implantation than C. difficile wild-type cells, suggesting that fibronectin is 
exploited to some extent as a molecular bridge to increase colonization of colonic 
surfaces by C. difficile (Barketi-Klai et al., 2011).  
 
4.3. Proteolytic enzymes 
Besides Cwp84 and Cwp13, other proteolytic enzymes are likely to play a 
role in early stages of colonization. An early study showed the production of 
hyaluronidase, collagenase and chondroitin-4-sulfatase by C. difficile (Seddon et 
al., 1990). A later study examined various C. difficile isolates and demonstrated 
that the supernatant of bacterial cultures contained enzymes that are able to 
degrade gelatin, collagen and azocoll (Poilane et al., 1998). However, the role of 
these enzymes in pathogenesis is unclear. They might act as auxiliary virulence 
factors that facilitate infiltration of C. difficile cells and toxins to the colonic 
mucosa.  
Also, proteolytic enzymes may play a role in releasing suitable substrates from 
available protein sources for metabolism (Seddon and Borriello, 1992; Poilane et 
al., 1998; Maeda, 1996).  
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AIM OF THE WORK 
 
 
To understand the mechanisms of host adaptation, establishment of the 
disease and transmission from a host to another, it is of outstanding importance 
to identify and characterize all the factors that are involved in the interaction 
between the pathogen and its host. So far, most efforts have been focused on 
characterization of clostridial toxins (toxin A and B, binary toxin), which are 
recognized as major virulence factors (Kuehne et al., 2010; Lyras et al., 2009; 
Voth and Ballard, 2005; Schwan et al., 2009). However it is evident that other 
factors, either exposed on the bacterial surface or released by the bacterium in the 
extracellular environment, are needed for bacterial fitness and 
establishment/transmission of disease.  
In recent years, the sequencing of several C. difficile genomes (Sebaihia et al., 
2006; He et al., 2013) and the spread of molecular tools that allow C. difficile 
genetic studies (Cartman et al., 2012; Kuehne et al., 2011) have led to the 
identification of a certain number of surface/secreted proteins and few of them 
have been associated to pathogenesis through in vitro and in vivo studies (Sarker 
and Paredes-Sabja, 2012). However, a systematic identification of C. difficile 
secreted proteins, which are either exposed on the cell surface or released in the 
environment, has been never carried out with success. Previous studies have tried 
to characterize the extracellular C. difficile protein profile through proteomic 
approaches, but in all cases the precise cellular localization of the proteins 
identified was unclear due to contamination with cytoplasmic proteins (Boetzkes 
et al., 2012; Wright et al., 2005; Mukherjee et al., 2002). 
In order to identify novel factors that could play a role in the host-pathogen 
interaction, first part of this work was aimed at comprehensively identifying 
surface-exposed and exported proteins of C. difficile. This was assessed taking 
advantage of a proteomic strategy. Two clinical isolates were analyzed: 630, 
Aim of the work 
 
24 
 
isolated from a case of pseudomembranous colitis (Wüst et al., 1982), and 
R20291, an important hypervirulent strain belonging to the BI/NAP1/027 
category (Loo et al., 2005; McDonald et al., 2005). 
Second part of this work was aimed at characterizing, among the identified 
surface or secreted proteins, novel factors likely involved in pathogenesis. 
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MATERIALS AND METHODS 
 
 
1. Bacterial strains and culture conditions 
Clostridium difficile 
C. difficile clinical isolates 630 and R20291 were used in this study. Bacteria 
were grown in liquid or solid media at 37°C under anaerobic conditions (80% 
N2, 10% CO2, 10% H2) in a Don Whitley workstation (Yorkshire, United 
Kingdom).  
For proteomic analysis, bacteria were cultured in chemically defined medium 
(CDMM) prepared as described by Karasawa (Karasawa et al., 1995) or in rich 
medium (BHIS or TYM). Bacteria from glycerol stocks were grown overnight 
on BHIS plates. One single colony was inoculated in 5 ml of the desired 
medium and grown overnight to stationary phase. The resulting culture was 
diluted in 5 ml of the same medium to a starting OD600 of 0.05 and grown to 
mid-exponential phase (0.4-0.8). The culture was diluted again to a starting 
OD600 of 0.05 in 50 ml of the same medium and grown again up to mid-
exponential phase (0.4-0.8). 
For the second selection in the genetic manipulation of C. difficile, a different 
minimal medium was used (CDM), prepared according to Cartman and co-
workers (Cartman et al., 2012). For immunoblotting analysis, bacteria were 
grown in TYM broth. For phenotypical characterization of 630/CD630_36690, 
bacteria were grown in BHIS broth.  
 
Escherichia coli 
E. coli strain DH5alpha (Invitrogen) was used for cloning, T7 Express (New 
England Biolabs) was used for recombinant proteins expression and 
purification. E. coli was cultured in liquid or solid Luria-Bertani (LB) medium 
supplemented with suitable antibiotics. To induce expression of recombinant 
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proteins in T7 Express, liquid medium EnPresso (Biosilta) containing 1 mM 
IPTG was used. 
Compositions of all the culture media used in this study are reported in 
Appendix 1. 
 
 
2. Proteomic analysis of C. difficile cell surface and culture supernatants 
Analysis of C. difficile surface 
To analyze the surface protein profile, after reaching the exponential phase 
of growth 50 ml cultures were centrifuged at 3200 g for 10 min at 4°C and the 
medium discarded. A wash step in PBS, pH 7.4 was performed. Then the 
bacterial pellet was resuspended in digestion buffer and the reaction incubated 
at 37°C. Several growth media, digestion buffer compositions and times of 
digestion were tested, trying to find a condition in which no bacterial lysis was 
detectable. In particular, we changed (i) growth medium (CDMM defined 
medium, BHIS and TYM rich media); (ii) osmotic conditions (to 750 µl TrisHcl 
50 mM, pH 7.5 an osmotic agent was added, either sucrose, in a concentration 
ranging from 0 to 33%, or NaCl, in a concentration ranging from 0 to 1 M); (iii) 
trypsin concentration (from 0 to 50 µg); (iv) time of digestion (from 15 min to 
16 h). 
After digestion, bacteria were pelleted by centrifugation at 16000 g for 10 min. 
The supernatant was filtered through a 0.22 µm filter. To obtain a peptide 
mixture suitable for HPLC separation, proteins contained in the pellet were 
digested in small peptides. 0.1% Rapigest (WatersTM, MA, USA) and 5mM 
DTT were added and the sample was boiled for 10 min. After cooling, pH was 
checked and eventually ammonium bicarbonate crystals were added to obtain a 
pH between 7.5 and 8.5. 1 µg of Trypsin was added and the digestion reaction 
was incubated overnight at 37°C. Digested samples were desalted for 
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LC/MS/MS analysis by reverse-phased chromatography, using OASIS 
Cartridges HLB 1cc (WatersTM, MA). 
 
Analysis of C. difficile culture supernatants 
To analyze the protein content of culture supernatants, after reaching the 
desired phase of growth in CDMM medium 50 ml cultures were centrifuged at 
3200 g for 10 min at 4°C and the medium transferred to a clean tube. The 
supernatant was filtered through a 0.22 µm filter in order to remove any 
remaining bacteria, and EDTA-free Complete protease inhibitor cocktail 
(Roche) plus 5 mM EDTA was added. Proteins were precipitated by addition of 
10% TCA, 0.04% sodium deoxycholate and incubation for 3 h in ice, followed 
by centrifugation at 37000 g for 20 min at 4°C. The pellet was resuspended in 
10% TCA and centrifuged as before. Pellets were washed three times with 
decreasing amounts of cold absolute ethanol (half volume, 1 ml, 200 µl), then 
dried in a vacuum concentrator and suspended in 50 mM ammonium 
bicarbonate; the pH was adjusted to 7.5-8.5 by adding ammonium bicarbonate 
crystals directly into the tube. 
To obtain a peptide mixture suitable for HPLC separation, proteins contained in 
the pellet were digested in small peptides. 0.1% Rapigest (WatersTM, MA, 
USA) and 5mM DTT were added and the sample was boiled for 10 min at 100 
°C. After cooling, 1 µg of Trypsin was added and the digestion reaction was 
incubated overnight at 37°C. Digested samples were desalted for LC/MS/MS 
analysis by reverse-phased chromatography, using OASIS Cartridges HLB 1cc 
(WatersTM, MA). 
 
Peptide separation and mass spectrometry analysis (LC/MS/MS) 
Peptides were separated by nano-LC on a NanoAcquity UPLC system 
(Waters) connected to a Q-ToF Premier Electro Spray Ionization (ESI) mass 
spectrometer equipped with a nanospray source (Waters). Samples were loaded 
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onto a NanoAcquity 1.7 μm BEH130 C18 column (75 μm X 25 mm, Waters) 
through a NanoAcquity 5 μm Symmetry® C18 trap column (180 μm X 20 mm, 
Waters).  Peptides were eluted with a 120-min gradient of 2–40% of 98% 
acetonitrile, 0.1% formic acid solution at a flow rate of 250 nl/min.  
The eluted peptides were subjected to an automated data-dependent acquisition 
using the MassLynx software, version 4.1 (Waters), in which a MS survey scan 
was used to automatically select multicharged peptides over the m/z ratio range 
of 300–2000 for further MS/MS fragmentation. Up to five different components 
were subjected to MS/MS fragmentation at the same time. After data 
acquisition, individual MS/MS spectra were combined, smoothed, and 
centroided using ProteinLynx, version 3.5 (Waters), to obtain the peak list file.  
The Mascot Daemon application (MatrixScience Ltd., London, UK) was used 
for the automatic submission of data files to a version of MASCOT (version 
2.2.1) running on a local server.  
Protein identification was achieved by searching in a locally curated database 
combining protein sequence data derived from the Clostridium difficile section 
of the NCBInr database, the total number of sequences and residues being 
57275 and 17440799, respectively. The MASCOT search parameters were set 
to (i) 4 as number of allowed missed cleavages for Trypsin digestion, (ii) 
methionine oxidation and glutamine and asparagine deamidation as variable 
modifications, (iii) 0.3 Da as peptide tolerance, and (iv) 0.3 Da as MS/MS 
tolerance. Only significant hits were considered, as defined by the MASCOT 
scoring and probability system. The score thresholds for acceptance of peptide 
identification were ≥48 for trypsin digestion.  
 
 
3. Bioinformatic prediction of protein subcellular localization 
All the nucleotide and aminoacid sequences of proteins were obtained from 
the NCBI database (http://www.ncbi.nlm.nih.gov/). 
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The presence of a signal peptide was predicted using the online software 
SignalP 4.0 (http://www.cbs.dtu.dk/services/SignalP/). Subcellular localization 
of proteins identified in culture supernatants was predicted using the online 
software PSORTb 3.0 (http://www.psort.org/psortb/). The presence of a 
putative prokaryotic lipoprotein motif in CD630_36690 was predicted using the 
online software PROSITE (http://prosite.expasy.org/). 
Aminoacid alignment of sequences of interest on the global protein database 
was carried out using blastp at http://blast.ncbi.nlm.nih.gov/Blast.cgi. 
For alignment of Zmp1 ATLF domain with Anthrax Lethal Factor C-terminal 
ATLF domain, the ClustalW2 software was used (http://pbil.univ-lyon1.fr/). 
 
 
4. Preparation of C. difficile and culture supernatant fractions 
To prepare a total cell extract (TE), strain 630 was grown in TYM to OD600 
1.3. Cells were harvested by centrifugation and the pellet was washed and 
resuspended in PBS. Cell lysis was carried out by freeze-thawing. 
In order to isolate the “mutanolysin extract” (ME), containing the S-layer 
proteins together with other proteins that are present within the cell wall, 
bacteria were grown in 20 ml of TYM to OD600 1.3. Cells were separated by 
centrifugation at 3200 g and washed once in PBS and once in Tris-sucrose 
buffer (10 mM Tris-HCl pH 6.9, 10 mM MgCl2, 0.5 M sucrose). The pellet was 
then incubated in 2 ml of digestion buffer (Tris-sucrose buffer with 250 µg/ml 
mutanolysin and protease inhibitors) for 2 h at 37°C with gentle agitation. The 
reaction was centrifuged to separate the supernatant containing the cell wall and 
S-layer fractions, from the pellet containing the protoplast fraction (P). 
Protoplasts were resuspended in PBS and lysed by freeze-thawing. 
The S-layer fraction (SL), containing only proteins associated to the S-layer, 
was prepared as described previously (Calabi et al., 2001). Bacteria were grown 
in 50 ml of TYM broth to OD600 1.3. Cells were separated from the medium by 
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centrifugation at 3500 g for 10 min at RT, washed in PBS and finally incubated 
in 0.5 ml of 0.2 M HCl, pH 2.2 for 20 min at RT with gentle agitation, in the 
presence of protease inhibitors. The bacterial suspension was centrifuged at 
maximum speed at 4°C for 10 min. The supernatant containing the S-layer 
proteins was removed and the pH neutralized by addition of 2 M Tris base. 
To prepare supernatant fractions, bacteria of strain 630 were grown in 100 ml 
TYM to OD600 1.3 and centrifuged at 3200 g to separate the culture supernatant 
(total supernatant, TS). Half of the total supernatant was ultracentrifuged at 
150000 g for 16 h at 4°C to obtain two fractions (ultracentrifugation pellet, UP, 
and ultracentrifugation supernatant, US). To prepare total supernatant and 
ultracentrifugation supernatant fractions for immunoblotting analysis, proteins 
were precipitated by addition of TCA, as described for LC/MS/MS analysis, 
and then resuspended in PBS. The ultracentrifugation pellet was immediately 
resuspended in PBS.  
 
 
5. Production of antibodies 
Primary antibodies used for immunoblotting analysis of cell and supernatant 
fractions are polyclonal mouse antisera raised against recombinant his-tagged 
proteins.  
To obtain a serum recognizing all the proteins released by C. difficile in culture 
supernatant,  C. difficile 630 was grown in CDMM to OD600 0.5. Cultures were 
centrifuged and culture supernatants filtered through 0.22 µm filters. Proteins 
present in this fraction were concentrated using Vivaspin centrifugal 
concentrators MWCO 5000 Da (Sigma). The resulting protein concentration 
was estimated with the bicinchoninic acid assay (Pierce, Rockford, IL, USA). 
Eight mice were immunized three times with 20 µg of protein mix per dose. 
The resulting sera were pooled and used in immunoblotting analysis. 
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6. Immunoblotting analysis 
For immunoblotting analysis of whole-cell lysates, cell fractions, 
supernatant fractions and purified recombinant proteins, the following amounts 
of cell and supernatant fractions were loaded:  
- TE: 10 µl of total extract 10x concentrated respect to the starting culture 
- P: 10 µl of protoplast extract 20x concentrated respect to the starting 
culture 
- ME: 10 µl of mutanolysin extract 10x concentrated respect to the starting 
culture 
- SL: 10 µl of S-layer extract 100x concentrated respect to the starting 
culture 
- TS, US and UP: 10 µl of total supernatant 10x concentrated respect to the 
starting culture for CD630_18300, CD630_02370 and CD630_23650; 10 µl of 
total supernatant 250x concentrated respect to the starting culture for 
CD630_36690 
- 10 ng of recombinant protein were loaded as a control 
For immunoblotting analysis of recombinant proteins with serum recognizing 
concentrated culture supernatants, the following amounts of recombinant 
proteins were loaded: 
- 200 ng of CD630_01830, CD630_02370, CD630_14690, CD630_21770, 
CD630_23650, CD630_27950, CD630_36690 
- 2 ng of CD630_05140 
All the samples were mixed with NuPage LDS Sample buffer (Invitrogen) and 
Sample Reducing Agent (Invitrogen) and heated for 10 min at 100°C prior to 
loading. 
Samples were separated by SDS-PAGE on a NuPAGE gel (Invitrogen) and 
transferred onto nitrocellulose membranes using an iBlot Dry Blotting System 
(Invitrogen). Membranes were blocked 1 h at RT by agitation in blocking 
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solution (10% skimmed milk, 0.05% Tween-20, in PBS). All the primary 
antibodies used were diluted 1:1000 in 1% skimmed milk, 0.05% Tween-20 in 
PBS and incubated 90 min at 37°C. After washing in 1% milk solution, the 
membranes were incubated in 1% milk solution in a 1:5000 dilution of 
peroxidase-conjugated goat anti-mouse serum (Dako) at RT for 45 min. After 
washing in PBS, 0.05% Tween-20, the resulting signal was detected using the 
Super Signal West Pico chemiluminescent substrate (Pierce) following the 
manufacturer's instructions. 
 
 
7. Site-directed mutagenesis 
The pET15-TEV expression vector containing the gene fragment encoding 
residues 27–220 of Zmp1 was used as a template for site-directed mutagenesis. 
This construct allows expression of a phusion protein constituted by an N-
terminal His6-tag, a cleavage site for TEV protease and a Zmp1 fragment 
corresponding to the full length protein lacking the predicted signal peptide. 
The E143A mutant was generated by site-directed mutagenesis using the 
polymerase incomplete primer extension (PIPE) system (Klock et al., 2009). 
Primers E143Af and E143Ar (Appendix 2) were used to substitute the GAA 
codon (glutamate) with the GCA codon (alanine). 
The H146A mutant was generated by site-directed mutagenesis using the 
GeneArt® Site-Directed Mutagenesis system (Invitrogen). Primers H146Af and 
H146Ar (Appendix 2) were used to substitute the CAT codon (histidine) with 
the GCT codon (alanine). Polymerase chain reaction was carried out following 
manufacturer‟s instructions. 
The resulting plasmids were used to transform the T7 Express E. coli strain 
(New England Biolabs). 
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8.  Protein expression and purification 
Protein expression was performed in T7 Express E. coli cells (New England 
Biolabs). To produce the His-tagged Zmp1 (CD630_28300) wild type or 
mutants, the cells were cultured overnight at 30°C in EnPresso medium (Biosilta-
Oulu, Finland) following the manufacturer‟s instructions. Protein expression was 
induced with 1 mM IPTG for 8 h at 30°C. The harvested cells were lysed by 
sonication in binding buffer (20 mM Tris-HCl, 300 mM NaCl, 10 mM imidazole, 
pH 8.0) and centrifuged. Tag-less proteins were obtained through a two-step 
purification protocol (Fig. 1). The supernatant was loaded onto a PD-10 gravity 
flow empty column (GE Healthcare, NJ, USA) packed with 2 ml of Ni-NTA FF 
resin (Qiagen GmbH, Hilden, Germany) equilibrated with the binding buffer. 
The protein was eluted with buffer containing 300 mM imidazole. Buffer was 
then exchanged in 50 mM TrisHCl, 0.5 M EDTA, 1 mM DTT, pH 8.0 (TEV 
buffer) by size exclusion chromatography (PD-10 desalting columns, GE 
Healthcare). Then, cleavage of the His-tag with the tobacco etch virus (TEV) 
protease (Invitrogen, 5 ng TEV for each µg of recombinant protein) was carried 
out at RT overnight. After digestion, TEV buffer was substituted with binding 
buffer and a second “subtractive” purification was performed on the Ni-NTA 
column. This step allows purification of the protein in the flow-through while cut 
His-tag, TEV protease, uncut protein and contaminants are retained inside the 
column. Protein concentrations were estimated with the BCA assay (Pierce, 
Rockford, IL, USA). The final purity quality of the proteins was checked by 
SDS-PAGE.  
To perform activity assays, the purified proteins were incubated with 20 mM 
EDTA overnight at 4°C to remove any bound divalent cation and buffer was 
exchanged with Tris buffer (50 mM Tris-HCl, 150 mM NaCl, pH 7.6) by size 
exclusion chromatography. Different metallated forms of Zmp1 were obtained by 
addition of ZnCl2, CuCl2 or NiCl2 solutions up to the desired final concentration. 
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Figure 1. Scheme representing the two-step procedure used for purification of tag-less 
recombinant proteins. (A) The 6His-tagged protein was purified by IMAC. Then the 6His tag was 
removed by incubation with TEV protease and a second “subtractive” IMAC was carried out. (B) 
During subtractive IMAC, the tagless protein is obtained in the flow-through, while cut His-tag, TEV 
protease, uncut protein and contaminants are retained inside the column. 
 
 
 
9. Collagenase/gelatinase fluorimetric assay 
Proteolytic activity was assayed using the Molecular Probes EnzChek 
Gelatinase/Collagenase Assay Kit (Invitrogen, USA) with DQ™ Gelatin from 
pig skin (E-12054) as a fluorescein-conjugate substrate. Analysis was 
performed using a 96-well plate approach and all assays were done in triplicate. 
Each well was set up with 100 µl reaction volume containing 100 µg/ml gelatin 
and 800 µg/ml of recombinant protein.  
As a positive control, 0.2 u/ml of control enzyme (purified collagenase type IV 
from Clostridium histolyticum) were used. Reactions were carried out in Tris 
buffer (50 mM Tris-HCl, 150 mM NaCl, pH 7.6) in the absence or presence of 
0.5 mM ZnCl2, CuCl2 or NiCl2. Reactions were allowed to proceed for up to 13 
h at 37°C. Readings were taken every 10 min using a 96-well fluorescent plate 
reader (Infinite M200 spectrophotometer microplate reader, Tecan) with 
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excitation/emission at 480/525 nm, respectively. All values were corrected 
against the fluorescent curve of a reaction containing everything except the 
protease. 
 
 
10. In vitro fibronectin cleavage assay 
To test for cleavage of fibronectin, 170 µg/ml of fibronectin from human 
plasma (SIGMA) were incubated at 37°C for 24 h in Tris buffer (50mM 
TrisHCl, 150mM NaCl, pH 7.6) in absence or presence of an equal amount of 
Zmp1 and in absence or presence of 0.5 mM ZnCl2, NiCl2 or CuCl2. Reactions 
were analyzed on a 3-8% NuPAGE gel (Invitrogen) by silver staining with 
SilverQuest (Invitrogen). 
 
 
11. Proteolytic activity of Zmp1 protein on human fibroblasts  
IMR-90 cells (Human fibroblasts, ATCC) were maintained in Eagle‟s 
Minimum Essential Medium (EMEM, ATCC) supplemented with 10% heat-
inactivated fetal bovine serum (FBS, Gibco) and antibiotics at 37°C in 5% CO2. 
To study Zmp1 activity, cells were seeded on 8-well chamber slides coated with 
collagen I (2.5 x 10
4
 per well) (BD BioCoat) and grown for 2 days. Cells were 
then incubated with 250 µg/ml of recombinant Zmp1 protein or mutant Zmp1 
proteins and 0.1 mM ZnCl2 for 16 h at 37°C, in EMEM without FBS to avoid 
the interference of plasma fibronectin. After washings, cells were fixed with 
3.7% paraformaldehyde. Samples were washed extensively and incubated with 
rabbit anti-fibronectin antibodies (Sigma-Aldrich) for 1 h at RT. After multiple 
washings, samples were incubated with Alexa Fluor 568 goat anti-rabbit IgG. 
Glass coverslips were mounted with ProLong
®
 Gold antifade reagent with 
DAPI and analyzed with a Zeiss LSM710 confocal microscope. 
Materials and methods 
 
36 
 
12. Differential scanning fluorimetry (DSF) 
The shifts in the melting temperature of Zmp1 wild type, E143A and H146A 
as a function of Zn
2+
 concentration were determined with DSF analysis, 
following the previously reported protocol (Niesen et al., 2007). In each well, 
apo protein was incubated at a concentration of 20 μM in 20 μl Tris buffer, in 
presence of ZnCl2 in a final concentration ranging from 0 to 0.5 mM.  The plate 
was subjected to a temperature gradient scan (25–95 °C) in a Real Time PCR 
machine (Agilent Technologies, Santa Clara, CA, USA). The fluorescence 
intensity was measured by use of fluorescence Sypro Orange dye (×5 final 
concentration) at different temperatures with excitation/emission wavelengths of 
490 and 575 nm, respectively.  
 
 
13. Generation of C. difficile 630/∆CD630_36690 deletion mutant 
Generation of the knock-out plasmid 
The 630/∆CD630_36690 strain was generated in the 630 background 
employing the allele exchange strategy described by Cartman and co-workers 
(Cartman et al., 2012) (Fig. 3). Two allele exchange cassettes were cloned into 
the pMTL-SC7315 vector (Fig. 2 and Fig. 3). Approximately 500 bp fragments 
of the flanking regions of the target gene were amplified by PCR from 630 
genomic DNA (isolated using a DNeasy Blood and Tissue kit, Qiagen). 
Amplification reaction was carried out with Phusion High-Fidelity DNA 
polymerase (New England BioLabs) using the primers couples U3669f/U3669r 
for amplification of the upstream cassette and D3669f/D3669r for amplification 
of the downstream cassette (Appendix 2). Primers have ends containing the 
appropriate restriction sites for cloning (U3669f and D3669r carry a PmeI site, 
U3669r and D3669f an EcorI site). Thermocycling conditions were 95°C for 5 
min, followed by 35 cycles of 95°C for 30 s, an appropriate annealing 
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temperature for 30 s, 72°C for 1 min/kb, and a final extension of 72°C for 10 
min. The upstream and downstream fragments were cloned into the PmeI site of 
pMTL-SC7315 by one-step ligation with T4 DNA ligase (Rapid DNA Ligation 
kit, Roche) to generate an in-frame deletion in the CD630_36690 open reading 
frame (deletion of nucleotides 4 to 558). The reaction was transformed in the E. 
coli cloning strain DH5alpha (Invitrogen) by heat shock. Selection of 
transformants was carried out on LB solid medium supplemented with 25 µg/ml 
chloramphenicol. Several colonies were picked and inoculated in liquid LB 
medium supplemented with 12.5 µg/ml chloramphenicol. Using standard 
plasmid extraction methods, plasmid was purified from each of the overnight 
cultures and screened by restriction analysis with PmeI and by PCR using 
primers couple SC7-F1/SC7-R1 (Appendix 2). Then the DNA sequence was 
checked by Sanger sequencing using primers SC7-F and SC7-R (Appendix 2). 
Restriction endonucleases were obtained from New England BioLabs and used 
according to the manufacturer's instructions.  
 
 
 
 
 
 
 
 
 
 
 
 
Figure 2. Map of pMTL-SC7315 vector for allele exchange. 
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Transfer of knock-out plasmid into the C.difficile recipient by 
conjugation 
A knockout cassette plasmid verified by sequencing was re-transformed into 
electrocompetent E.coli conjugation donor strain CA434, carrying out selection 
on LB plates supplemented with 20 µg/ml chloramphenicol. Recipient strain C. 
difficile 630 and donor strain E. coli CA434/pMTL-SC7315 were grown 
overnight in BHIS and in LB/12.5 µg/ml chloramphenicol, respectively. 1 ml of 
the stationary overnight culture of E. coli donor strain was pelleted, washed and 
the cells were re-suspended in 0.5 ml PBS. The conjugal donor pellet was then 
resuspended in 200 µl of stationary overnight culture of conjugal recipient cells 
and the entire conjugation mixture was pipetted onto a single BHIS non-
selective plate in discrete drops. After 24 h of incubation under anaerobic 
conditions (to allow conjugal transfer of the knockout plasmid from the E. coli 
donor to the C. difficile recipient) all growth was harvested into 500 µl PBS and 
plated onto BHIS plates containing D-cycloserine (250 µg/ml), cefoxitin (8 
µg/ml) and thiamphenicol (115 µg/ml) to select for transconjugants (i.e. C. 
difficile cells harbouring the plasmid). Plates were incubated at 37°C under 
anaerobic conditions for 24-72 h. 
 
Isolation of single cross-over clones 
Transconjugant colonies were restreaked and incubated 24-72 h at 37°C. 
Single cross-over clones were identified as faster growing colonies in amongst 
slower growing transconjugant colonies. Single cross-over clones were purified 
by picking and restreaking and then confirmed by PCR analysis carried out with 
Platinum Taq (Invitrogen) in Failsafe PCR buffer E (Epicentre) using primers 
pairs ext3669f/SC7-F1, int3669f/SC7-F1, SC7-R1/int3669r, SC7-R1/ext3669r 
(Appendix 2) (Fig. 3).  
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Isolation of double cross-over clones 
To allow rare second recombination events to occur, single-crossover clones 
were restreaked onto nonselective BHIS medium and incubated for 96 h. All 
growth was harvested in 500 µl PBS, serial dilutions were made (from 10
-1
 to 
10
-6
), and 100 µl of each dilution were plated onto CDM supplemented with 50 
µg/ml 5-fluorocytosine (FC). After 48 h of incubation, FC-resistant clones were 
patch plated onto BHIS supplemented with cycloserine, cefoxitin, and 
thiamphenicol to screen for plasmid loss. Fluorocytosine-resistant 
thiamphenicol-sensitive clones were analyzed by PCR to distinguish double-
crossover recombinant clones from wild-type revertant clones, using primers 
ext3669f/ext3669r (Appendix 2). Sanger sequencing was used to confirm the 
expected genotype (Fig. 3). 
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Figure 3. Scheme representing the allele exchange strategy used to generate deletion mutants in C. 
difficile.  
 
 
14. Vital counts of C. difficile spores 
Sporulating cultures of C. difficile were prepared in BHIS broth. At different 
times, samples (500 μl) were treated with 50% ethanol for 1 h inside the 
anaerobic chamber to selectively kill the vegetative cells (Borriello and Honour, 
1981). Samples were then washed once with 1 ml PBS, serially diluted in PBS, 
and plated onto BHIS agar supplemented with 0.1% taurocholate (Sigma, 
United Kingdom). CFU were enumerated after incubation for 24 h inside the 
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anaerobic chamber.  As a control, total counts of vegetative cells and spores 
were determined by plating dilutions of untreated culture on the same medium.  
 
 
15. Confocal immunofluorescence microscopy 
C. difficile 630 was grown in BHIS broth to OD600 1.3. Cells were pelleted 
by centrifugation at 3200 g for 10 min at 4°C, washed in PBS and then fixed in 
double volume of PBS/4% formaldehyde for 20 min at RT. After washing in 
PBS, cells were resuspended in the equal volume of PBS and 20 µl of bacterial 
solution were spotted on a glass slide pretreated with a 10% V/V solution of 
0.1% poly-lysine (Sigma). Blocking was carried out with 3% BSA in PBS for 
20 min at RT. Primary antibody was diluted 1:500 in 1% BSA/PBS for 1 h at 
RT. After 3 washes in PBS, slides were incubated with Alexa Fluor® 568 Goat 
Anti-Mouse IgG (H+L) (Invitrogen) diluted 1:400 in 1% BSA/PBS for 30 min 
at RT. Slides were washed 3 times in PBS and mounted with ProLong Gold 
Antifade Reagent with DAPI (Invitrogen). Slides were analyzed with Zeiss 
LSM710 confocal microscope. 
 
 
16. Electron microscopy 
Droplets of OMV suspension (10 µl) were placed on formvar-carbon coated 
grids and allowed to adsorb for 60 s. Excess liquid was removed gently touching 
the filter paper. The adsorbed specimen was then fixed for 2 min at room 
temperature floating on a drop of 4 % paraformaldehyde plus 0.05% 
glutaraldehyde in PBS, pH 7.2. Negative-staining was performed by first 
washing the specimen grid on a drop of negative stain (2% uranyl acetate in 
distilled water), blotting and repeating this step once more, this time leaving the 
specimen grid for 60 s on a new drop of negative stain solution.  
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Samples were observed at a JEOL 1200 EX II electron microscope. Micrographs 
were acquired by the Olympus SIS VELETA CCD camera equipped  with the 
iTEM software. 
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RESULTS 
 
 
1. Identification of surface and secreted proteins of C. difficile by mass 
spectrometry 
1.1. Experimental approach 
In order to comprehensively identify proteins of C. difficile that are 
associated to the surface or released in the extracellular environment, two 
different proteomic approaches were tried (Fig. 1).  
The first approach, known as “surface shaving”, has successfully been used to 
characterize the surface protein profile of several bacterial species (Bensi et al., 
2012; Doro et al., 2009; Rodriguez-Ortega et al., 2006; Berlanda Scorza et al., 
2008). After growth in liquid medium, bacteria are treated with trypsin, a 
protease that should act on the bacterial surface releasing into the medium a 
mixture of peptides deriving from surface proteins. These peptides are then 
recovered, separated by liquid chromatography and analyzed by mass 
spectrometry (LC/MS/MS). 
The second approach, based on a similar analysis of culture supernatants 
(Desvaux et al., 2010; Bensi et al., 2012), is aimed at identifying proteins that 
are released by bacteria in the medium during growth. Proteins contained in 
culture medium are precipitated and then digested with trypsin in order to 
produce a mixture of peptides that can be analyzed by LC/MS/MS. 
For this analysis, two clinical isolates were selected, 630 and R20291. 630 is a 
reference strain for C. difficile, as it is the first for which genome sequencing 
was completed (Sebaihia et al., 2006). It was isolated from a case of 
pseudomembranous colitis (Wüst et al., 1982). R20291 is an important 
epidemic strain belonging to the category BI/NAP1/027, which caused an 
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increase in rates and severity of CDAD in North America and Europe (Loo et 
al., 2005; McDonald et al., 2005).  
 
 
 
 
Figure 1. Scheme representing the two proteomic approaches used to identify surface and 
released proteins of C. difficile. 
 
 
1.2. Set up of growth conditions for proteomic analysis 
For proteomic analyses, bacteria were grown in the desired medium to the 
exponential phase of growth (OD600 0.4-0.8). Growth curves were performed 
for both strains 630 and R20291 in all the media in order to identify the range 
of optical density in which the cultures are in exponential phase (Fig. 2A). Both 
strains showed similar growth profiles, reaching maximum OD600 of 1.2-1.3 in 
chemically defined medium and of 1.8-2.0 in rich media (Fig. 2A). To analyze 
bacteria and culture media in exponential phase, bacteria were collected in a 
range of OD600 between 0.4 and 0.8. In order to minimize the amount of 
bacterial cell lysis, and subsequent contamination with cytoplasmic proteins, 
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bacteria were grown to the exponential phase multiple times, as described in 
Methods, before collecting supernatant samples for LC/MS/MS analysis.  
Quantitation of spores from cultures used for sample preparation revealed a 
very low percentage of spores (0.01%), suggesting an irrelevant contribution of 
proteins originating from them (Fig. 2B). 
 
 
 
 
Figure 2. Growth profile and vital counts of vegetative cells and spores for strain 630 in CDMM. 
(A) Growth curve of strain 630 in CDMM (growth curves were performed in triplicate). R20291 strain 
showed a similar growth profile. (B) Vital counts of vegetative cells and spores of strain 630 grown in 
CDMM. 
 
 
1.3. Analysis of C. difficile cell surface 
For surface shaving of C. difficile, several experimental conditions were 
tested (Table 1). However, in all cases a high amount of cytoplasmic proteins 
was detected in the reaction mixture (data not shown), indicating bacterial lysis. 
The analysis was carried out on both 630 and R20291 strains, as different 
bacterial isolates could respond differently to enzymatic treatments due to 
differences in their surface organization; however with both isolates a similar 
amount of bacterial lysis was observed. Several growth media (BHIS, TYM, 
CDMM and BHIS agar) were tested, in an attempt to minimize the physiologic 
lysis that takes place during bacterial growth. Moreover, many different 
A B
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conditions were changed for the shaving reaction. On one side, given the 
importance of an osmotic agent in preventing cell lysis, two osmotic agents 
(sucrose and NaCl) were tested at different concentrations. On the other side, 
several concentrations of protease were tried, including low concentrations 
(0.25 and 2.5 µg/ml), in an attempt to carry out a weaker surface digestion, and 
high concentrations (65 µg/ml), in an attempt to increase the ratio between the 
number of surface peptides and the number of cytoplasmic proteins released 
into the reaction mixture. To understand if trypsin was involved in bacterial 
lysis (i.e., causing a very rapid digestion, with subsequent disruption of cells), 
we performed control reactions in digestion buffer containing everything but 
trypsin; however also in this case we detected a large percentage of cytoplasmic 
proteins, indicating that other factors than trypsin must be involved in bacterial 
lysis. 
Presence of cytoplasmic proteins in the samples does not allow to assign the 
identified proteins to the correct subcellular compartment. Therefore, this 
approach did not allow the identification of C. difficile surface proteins. 
 
 
 
 
 
 
Table 1. Experimental conditions tested for surface shaving of C. difficile. 
 
 
 
Strain Growth medium Osmotic agent
Trypsin 
concentration
Time of trypsin 
incubation
630 TYM Sucrose (0-33%) 0 µg/ml 15'
R20291 CDMM NaCl (0-1 M) 0,25 µg/ml 20'
BHI 2,5 µg/ml 30'
BHI agar 13 µg/ml 2 h
65 µg/ml 16 h
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1.4. Analysis of C. difficile culture supernatants 
Analysis of 630 and R20291 culture supernatants led to the identification of 
a total of 51 proteins for strain 630 (from 6 experiments) and 30 proteins for 
R20291 (from 3 experiments) (Tables 2 and 3, Fig. 3). There was a considerable 
overlap (25 proteins) between the proteins identified in the two strains; however 
26 proteins were detected only in 630 and 5 only in R20291, although all the 
coding genes, except CD630_23880 and CDR20291_2278, are present in both 
genomes with at least 80% identity. We observed extremely low numbers of 
predicted cytoplasmic proteins, indicating insignificant levels of bacterial cell 
lysis during growth (Tables 2 and 3).  
Interestingly, majority of the proteins identified were putative surface-
associated proteins (Fig. 3). We grouped most of these proteins into five major 
classes, based primarily on the presence of domains responsible for surface 
association and secondly on the presence of conserved functional domains: 
CWPs (cell wall proteins), LPXTG-anchored proteins, extracellular hydrolases, 
transporters and flagellar proteins.  
Based on the presence of domains potentially responsible for surface 
association, we found 14 proteins containing the cell wall binding repeat 2 
domain (pfam04122), which is characteristic of the clostridial cell wall proteins 
(CWPs) (Sebaihia et al., 2006). These include previously studied proteins such 
as CwpV (Emerson et al., 2009; Reynolds et al., 2011), Cwp84 (Janoir et al., 
2007; Kirby et al., 2009), Cwp66 (Waligora et al., 2001), Cwp2 (Calabi et al., 
2002b; de la Riva et al., 2011), SlpA (Calabi et al., 2001; Fagan et al., 2009). 
Interestingly, Cwp24, recently annotated as a pseudogene or gene remnant in 
strain 630 (Monot et al., 2011), was identified in both 630 and R20291.  
We also identified two proteins (CD630_28310, CD630_01830) containing a 
LPXTG-like motif at the C-terminus, a motif associated with sortase-mediated 
anchoring to the peptidoglycan (Sebaihia et al., 2006).  
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A number of cell wall hydrolases with extracellular or membrane localization 
were detected. Among them, the previously characterized autolysin Acd 
(Dhalluin et al., 2005). Also, numerous ABC transporters, predicted to be 
involved in the uptake of sugars, amino acids, peptides, or inorganic ions were 
identified. Flagellar components were also a major protein family detected in 
the culture supernatants; notably, whereas the major flagellar subunit (FliC) was 
present in both strains, other proteins predicted to be part of the basal body, 
hook and cap structures were identified only in 630. It is possible that R20291 
flagella are less easily detached from the cell, as compared with 630 or their 
components are less expressed in the growth conditions tested in this study.  
Six proteins annotated as hypothetical, for which a function has not been 
predicted yet, were also detected (Table 2, Fig. 3). For most of them, a cellular 
localization could not be predicted by PSORTb. However, a cleavage site for 
signal peptidase could be predicted using SignalP for all of them. 
We did not detect C. difficile toxins A and B in the supernatants. As it is known 
from the literature, these toxins are produced after several hours of stationary 
phase and expression is downregulated at the transcriptional level in the 
presence of glucose (Mukherjee et al., 2002). Therefore it is not surprising that 
the two C. difficile major toxins were not detected in the experimental 
conditions used . 
Thus, using a proteomic approach, we have identified a subset of putative 
surface proteins that are extracellular to C. difficile. 
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Family Gene annotation (630) 
Locus tag 
630 
Signal 
peptide 
Manually 
cured 
PSORTb 
output 
630 
SN 
R20291 SN  
(locus tag) 
CWPs precursor of the S-layer proteins (SlpA) CD630_27930 yes cell wall yes CDR20291_2682 
  cell wall binding protein (Cwp2) CD630_27910 yes cell wall yes CDR20291_2680 
  cell wall binding protein (Cwp11) CD630_27950 yes cell wall yes CDR20291_2684 
  hemagglutinin/adhesin (CwpV) CD630_05140 yes cell wall yes nd 
  cell surface protein penicillin-binding protein (Cwp20) CD630_14690 yes cell wall yes nd 
  pseudogene (Cwp24) CD630_21930 yes cell wall yes CDR20291_2099 
  cell wall-binding protein (Cwp18) CD630_10470 yes cell wall yes nd 
  cell surface protein (Cwp66) CD630_27890 yes cell wall yes nd 
  cell wall binding protein (Cwp12) CD630_27940 yes cell wall yes CDR20291_2683 
  cell wall binding protein (Cwp9) CD630_27980 yes cell wall yes nd 
  cell surface protein (Cwp84) CD630_27870 yes cell wall yes nd 
  cell wall-binding protein (Cwp25) CD630_08440 yes cell wall no CDR20291_0774 
  N-acetylmuramoyl-L-alanine amidase, autolysin (Cwp6) CD630_27840 yes cell wall yes CDR20291_2672 
  N-acetylmuramoyl-L-alanine amidase (Cwp16) CD630_10350 yes membrane yes CDR20291_0891 
LPXTG-like adhesin CD630_28310 yes cell wall no CDR20291_2722 
  cell wall hydrolase CD630_01830 yes extracellular yes CDR20291_0184 
Extracellular 
hydrolases 
cell-wall hydrolase CD630_27680 yes extracellular yes CDR20291_2656 
peptidoglycan-binding/hydrolysing protein CD630_23880 yes unknown yes - 
  peptidoglycan-binding/hydrolysing protein - no unknown - CDR20291_2278 
  hydrolase CD630_24800 yes unknown yes nd 
  cell wall hydrolase; phosphatase-associated protein CD630_24020 yes extracellular yes nd 
  mannosyl-glycoprotein endo-beta-N-acetylglucosamidase (Acd) CD630_13040 yes extracellular yes CDR20291_1145 
  polysaccharide deacetylase CD630_15220 yes extracellular yes CDR20291_1371 
  lytic transglycosylase CD630_02260 no membrane* yes nd 
  LmbE-like deacetylase  CD630_27900 no membrane** yes nd 
Transporters ABC transporter sugar-family extracellular solute-binding protein CD630_08730 yes extracellular* yes CDR20291_0802 
  ABC transporter sugar-family extracellular solute-binding protein CD630_08760 yes extracellular* yes CDR20291_0805 
  ABC transporter iron-family extracellular substrate-binding protein CD630_16500 yes extracellular* yes CDR20291_1548 
  ABC transporter cystine/aminoacid-family extracellular solute-binding protein  CD630_21770 yes extracellular* yes CDR20291_2083 
  ABC transporter oligopeptide-family solute-binding protein CD630_26720 yes extracellular* yes CDR20291_2560 
  ABC transporter cystine/aminoacid-family extracellular solute-binding protein CD630_21740 yes extracellular* yes nd 
  ABC transporter nitrate/sulfonate/taurine extracellular solute-binding protein CD630_23650 yes extracellular* yes CDR20291_2252 
  multidrug efflux pump CD630_24080 yes membrane* yes CDR20291_2298 
Flagellar 
proteins 
flagellar hook-associated protein FlgK (or HAP1) CD630_02310 no extracellular* yes nd 
flagellar hook-associated protein 2 FliD (or HAP2) CD630_02370 no flagellar yes nd 
  flagellin C CD630_02390 no extracellular* yes CDR20291_0240 
  flagellar hook protein FlgE (Distal rod protein) CD630_02550 no flagellar yes nd 
  flagellar basal body rod protein FlgG CD630_02690 no flagellar yes nd 
  flagellar basal-body rod protein FlgB  CD630_02450 no extracellular* yes nd 
  flagellar hook-associated protein FlgL (or HAP3) CD630_02320 no extracellular yes nd 
  flagellar basal-body rod protein FlgC CD630_02460 no extracellular* yes nd 
Hypothetical 
proteins 
hypothetical protein CD630_36690 yes unknown yes CDR20291_3529 
hypothetical protein CD630_28300 yes unknown yes CDR20291_2721 
  hypothetical protein CD630_21270 yes membrane yes nd 
  hypothetical protein CD630_05490 yes unknown yes CDR20291_0474 
  hypothetical protein CD630_11560 yes unknown yes nd 
  hypothetical protein CD630_22510 yes unknown yes CDR20291_2151 
Other 
predicted 
surface 
proteins 
pilin protein CD630_35130 yes membrane yes nd 
Signal peptidase I, S26A family  CD630_13310 no cell wall yes nd 
SH3-domain-containing protein CD630_11350 yes extracellular yes CDR20291_0971 
calcium-binding adhesion protein CD630_27970 yes unknown yes nd 
Predicted 
cytoplasmic 
proteins 
translation inhibitor endoribonuclease  CD630_25130 no cytoplasmic yes nd 
enolase (2-phosphoglycerate dehydratase)  CD630_31700 no cytoplasmic yes nd 
glyceraldehyde-3-phosphate dehydrogenase CD630_31740 no cytoplasmic no CDR20291_3030 
  elongation factor Tu  CD630_00580 no cytoplasmic yes CDR20291_0051 
  XkdK-like protein  CD630_13630 no cytoplasmic no CDR20291_1206 
 
Table 2. List of proteins detected by LC/MS/MS in C. difficile 630 and R20291 culture 
supernatants 
1. Proteins identified have been divided in families based primarily on the presence of motifs for 
association to the peptidoglycan and secondly on the presence of conserved functional domains.  
2. Presence of a signal peptide was predicted with SignalP 4.0 using the 630 aminoacid sequence 
(except for CDR20291_2278, for which a sequence with aminoacid identity >40% is not present in 
630).  
3. Cellular localization was predicted with PSORTb 3.0 using the 630 aminoacid sequence (except for 
CDR20291_2278); the software output is reported, if not indicated with * (manually cured, deduced by 
similarity) or ** (manually cured, associated to the major S-layer locus).  
4. Detection in 630 culture supernatants (6 replicates) is indicated with „yes‟; „no‟ indicates that in 630 
an a.a. sequence homologous to the R20291 sequence is present, but the protein was not detected; „-‟ 
indicates that in 630 an a.a. sequence homologous to the R20291 sequence is not present .  
5. Detection in R20291 culture supernatants (3 replicates) is indicated with the locus tag; „nd‟ indicates 
that in R20291 an a.a. sequence homologous to the 630 sequence is present, but the protein was not 
detected; „-‟ indicates that in R20291 an a.a. sequence homologous to the 630 sequence is not present. 
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Figure 3. Family distribution of putative surface/released proteins detected in 630 (51 proteins) 
and R20291 (30 proteins) culture supernatants. Proteins identified have been divided in families 
based on the presence of motifs for association to the peptidoglycan and on the presence of conserved 
functional domains.  
 
 
 
 
 
630 R20291
  
Family Gene annotation (630) Locus tag 630 Presence in CD630 supernatant Presence in CDR20291 supernatant (locus tag) 
      Exp 1 Exp 2 Exp 3 Exp 4 Exp 5 Exp 6 Exp 1 Exp 2 Exp 3 
CWPs precursor of the S-layer proteins (SlpA) CD630_27930 X X X X X X CDR20291_2682 CDR20291_2682 CDR20291_2682 
  cell wall binding protein (Cwp2) CD630_27910     X     X   CDR20291_2680 CDR20291_2680 
  cell wall binding protein (Cwp11) CD630_27950     X     X     CDR20291_2684 
  hemagglutinin/adhesin (CwpV) CD630_05140   X   X X X       
  cell surface protein penicillin-binding protein (Cwp20) CD630_14690 X X X X X X       
  pseudogene (Cwp24) CD630_21930 X   X X X X CDR20291_2684 CDR20291_2684 CDR20291_2684 
  cell wall-binding protein (Cwp18) CD630_10470     X             
  cell surface protein (Cwp66) CD630_27890     X             
  cell wall binding protein (Cwp12) CD630_27940     X           CDR20291_2683 
  cell wall binding protein (Cwp9) CD630_27980     X             
  cell surface protein (Cwp84) CD630_27870         X         
  cell wall-binding protein (Cwp25) CD630_08440             CDR20291_0774     
  N-acetylmuramoyl-L-alanine amidase, autolysin (Cwp6) CD630_27840 X X X X X X CDR20291_2672 CDR20291_2672 CDR20291_2672 
  N-acetylmuramoyl-L-alanine amidase (Cwp16) CD630_10350 X   X     X     CDR20291_0891 
LPXTG-like adhesin CD630_28310             CDR20291_2722     
  cell wall hydrolase CD630_01830 X X X X X X CDR20291_0184 CDR20291_0184 CDR20291_0184 
Extracellular hydrolases cell-wall hydrolase CD630_27680 X X X X X X CDR20291_2656 CDR20291_2656 CDR20291_2656 
peptidoglycan-binding/hydrolysing protein CD630_23880 X   X     X       
  peptidoglycan-binding/hydrolysing protein -             CDR20291_2278 CDR20291_2278 CDR20291_2278 
  hydrolase CD630_24800 X   X X X X       
  cell wall hydrolase; phosphatase-associated protein CD630_24020 X X X             
  mannosyl-glycoprotein endo-beta-N-acetylglucosamidase (Acd) CD630_13040     X           CDR20291_1145 
  polysaccharide deacetylase CD630_15220     X           CDR20291_1371 
  lytic transglycosylase CD630_02260 X   X             
  LmbE-like deacetylase  CD630_27900 X   X   X X       
Transporters ABC transporter sugar-family extracellular solute-binding protein CD630_08730 X X X X X X CDR20291_0802 CDR20291_0802 CDR20291_0802 
  ABC transporter sugar-family extracellular solute-binding protein CD630_08760     X X     CDR20291_0805 CDR20291_0805 CDR20291_0805 
  ABC transporter iron-family extracellular substrate-binding protein CD630_16500   X X X X X CDR20291_1548 CDR20291_1548 CDR20291_1548 
  ABC transporter cystine/aminoacid-family extracellular solute-binding protein  CD630_21770 X X X X X X   CDR20291_2083 CDR20291_2083 
  ABC transporter oligopeptide-family solute-binding protein CD630_26720 X X X X X X CDR20291_2560 CDR20291_2560 CDR20291_2560 
  ABC transporter cystine/aminoacid-family extracellular solute-binding protein CD630_21740     X             
  ABC transporter nitrate/sulfonate/taurine extracellular solute-binding protein CD630_23650 X   X X X X CDR20291_2252   CDR20291_2252 
  multidrug efflux pump CD630_24080     X       CDR20291_2298     
Flagellar proteins flagellar hook-associated protein FlgK (or HAP1) CD630_02310 X   X X X X       
flagellar hook-associated protein 2 FliD (or HAP2) CD630_02370 X X X X X X       
  flagellin C CD630_02390 X X X X X X CDR20291_0240 CDR20291_0240 CDR20291_0240 
  flagellar hook protein FlgE (Distal rod protein) CD630_02550 X   X X X X       
  flagellar basal body rod protein FlgG CD630_02690 X         X       
  flagellar basal-body rod protein FlgB  CD630_02450 X                 
  flagellar hook-associated protein FlgL (or HAP3) CD630_02320 X X X   X X       
  flagellar basal-body rod protein FlgC CD630_02460 X   X   X X       
Hypothetical proteins hypothetical protein CD630_36690     X     X     CDR20291_3529 
hypothetical protein CD630_28300 X   X X X X     CDR20291_2721 
  hypothetical protein CD630_21270 X   X   X X       
  hypothetical protein CD630_05490 X X X   X X   CDR20291_0474 CDR20291_0474 
  hypothetical protein CD630_11560     X     X       
  hypothetical protein CD630_22510     X       CDR20291_2151     
Other predicted surface 
proteins 
pilin protein CD630_35130     X             
Signal peptidase I, S26A family  CD630_13310     X   X X       
  SH3-domain-containing protein CD630_11350     X   X     CDR20291_0971 CDR20291_0971 
  calcium-binding adhesion protein CD630_27970     X     X       
Predicted cytoplasmic proteins translation inhibitor endoribonuclease  CD630_25130           X       
enolase (2-phosphoglycerate dehydratase) (2-phospho-D-glycerate hydro-lyase) CD630_31700           X       
glyceraldehyde-3-phosphate dehydrogenase CD630_31740                 CDR20291_3030 
  elongation factor Tu  CD630_00580         X   CDR20291_0051   CDR20291_0051 
  XkdK-like protein  CD630_13630                 CDR20291_1206 
            Table 3. List of proteins detected in each experiment in C. difficile 630 and R20291 culture supernatants. 
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2. C. difficile 630 produces membrane vesicles during growth in vitro, but 
these are not responsible for the massive release of proteins observed 
during growth 
2.1. Working hypothesis 
We hypothesized several mechanisms by which C. difficile could release a 
high number of surface-associated proteins in culture supernatants (Fig. 4). 
Proteins could be released as single units, not in association to larger complexes, 
through a passive release (shedding) or through an active cleavage on the 
bacterial surface. It has already been shown that surface proteases, such as 
Cwp84 and Cwp13, are involved in C. difficile surface remodeling (de la Riva et 
al., 2011; Kirby et al., 2009). On the other side, proteins could be released in the 
extracellular environment in association to macromolecular structures, such as 
cell wall fragments or membrane vesicles (Fig. 4). 
Membrane vesicles have been extensively involved in the release of proteins in 
Gram-negative species (Wai et al., 2003; Kesty & Kuehn, 2004; Bomberger et 
al., 2009). More recently, similar structures have been observed in supernatants 
of Gram-positive bacteria (Gurung et al., 2011; Rivera et al., 2010). We decided 
to further investigate this hypothesis through mass spectrometry and electron 
microscopy analyses on culture supernatants. 
 
Figure 4. Scheme representing possible mechanisms by which C. difficile could release surface-
associated proteins in the extracellular environment. 
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2.2. Mass spectrometry analysis of 630 supernatant ultracentrifugation 
fractions 
We hypothesized that heavy macromolecular structures, such as cell wall 
fragments or membrane vesicles, should be spinned down in the pellet during 
ultracentrifugation of culture supernatants. To evaluate this hypothesis, C. 
difficile 630 was grown in chemically defined medium to exponential phase. 
After removal of all the bacterial cells, culture supernatant was ultracentrifuged 
to obtain two fractions: an ultracentrifugation supernatant (UC SN) and an 
ultracentrifugation pellet (UC P). Mass spectrometry analysis of the protein 
content was carried out on both fractions as well as on the total supernatant in 
two experiments (Table 4). 
The protein content of culture supernatant before and after ultracentrifugation 
was comparable, suggesting that most proteins are not released in association 
with large structures (Table 4). In accordance with this observation, we detected 
few proteins in the ultracentrifugation pellet (Table 4). Among them, we could 
detect the S-layer proteins, which are very abundant on the bacterial surface, 
flagellar proteins and a CWP (Cwp24). 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
  
Family 
  
Gene annotation (630) 
  
Locus tag 630 
  
exp5 exp5 exp5 exp6 exp6 exp6 
TOT SN UC SN UC P TOT SN UC SN UC P 
CWPs precursor of the S-layer proteins (SlpA) CD630_27930 X X X X X X 
  cell wall binding protein (Cwp2) CD630_27910   
 
  
 
X   
  cell wall binding protein (Cwp11) CD630_27950   
 
  
 
X   
  hemagglutinin/adhesin (CwpV) CD630_05140 X X   X X   
  cell surface protein penicillin-binding protein (Cwp20) CD630_14690   X   
 
X   
  pseudogene (Cwp24) CD630_21930 X X X X X   
  cell surface protein (Cwp84) CD630_27870   X   
  
  
  N-acetylmuramoyl-L-alanine amidase, autolysin (Cwp6) CD630_27840 X X   X X   
  N-acetylmuramoyl-L-alanine amidase (Cwp16) CD630_10350         X   
LPXTG-like cell wall hydrolase CD630_01830 X X   X X   
Extracellular hydrolases cell-wall hydrolase CD630_27680 X X   X X   
peptidoglycan-binding/hydrolysing protein CD630_23880   
 
  X X   
  hydrolase CD630_24800   X   
 
X   
  LmbE-like deacetylase  CD630_27900   X   X X   
Transporters ABC transporter sugar-family extracellular solute-binding protein CD630_08730 X X   X X   
  ABC transporter iron-family extracellular substrate-binding protein CD630_16500 X 
 
  X 
 
  
  ABC transporter cystine/aminoacid-family extracellular solute-binding protein  CD630_21770   X   X X   
  ABC transporter oligopeptide-family solute-binding protein CD630_26720   X   
 
X   
  ABC transporter nitrate/sulfonate/taurine extracellular solute-binding protein CD630_23650   X     X   
Flagellar proteins flagellar hook-associated protein FlgK (or HAP1) CD630_02310 X X   X X   
  flagellar hook-associated protein 2 FliD (or HAP2) CD630_02370 X X X X X   
  flagellin C CD630_02390 X X X X X X 
  flagellar hook protein FlgE (Distal rod protein) CD630_02550   X   X X   
  flagellar basal body rod protein FlgG CD630_02690 X X   X X   
  flagellar hook-associated protein FlgL (or HAP3) CD630_02320 X X   X X   
  flagellar basal-body rod protein FlgC CD630_02460   X   X X   
Hypothetical proteins hypothetical protein CD630_36690         X   
hypothetical protein CD630_28300 X X   X X   
  hypothetical protein CD630_21270   X   X X   
  hypothetical protein CD630_05490   X   X X   
  hypothetical protein CD630_11560       X     
Other predicted surface proteins Signal peptidase I, S26A family  CD630_13310   X     X   
SH3-domain-containing protein CD630_11350   X   
  
  
  calcium-binding adhesion protein CD630_27970         X   
Predicted cytoplasmic proteins translation inhibitor endoribonuclease  CD630_25130         X   
enolase (2-phosphoglycerate dehydratase) (2-phospho-D-glycerate hydro-lyase) CD630_31700   
 
  
 
X   
elongation factor Tu  CD630_00580   X         
         
        Table 4. Proteins detected in 630 ultracentrifugation fractions (experiments 5 and 6 from Table 3). 
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2.3. Electron microscopy analysis of 630 supernatant ultracentrifugation 
fractions 
Ultracentrifugation pellets were analyzed by electron microscopy. Flagellar-
like structures were identified, indicating that flagella are released as entire 
structures, probably because of surface remodeling (Fig. 5). These structures 
have a diameter of approximately 12 nm, compatible with a bacterial flagellum. 
Also, a small amount of vesicular-like structures were observed. These structures 
presented variable sizes, ranging from ~50 nm to ~200 nm of diameter (Fig. 5). 
Mass spectrometry analysis of ultracentrifugation pellet suggested that these 
structures are not involved in the massive release of surface proteins that we have 
observed (Table 4). Nevertheless, this is an interesting observation as membrane 
vesicles were never detected previously in clostridial culture media. 
 
 
 
 
 
Figure 5. Electron microscopy analysis of the ultracentrifugation pellet of 630 culture supernatant. 
Flagellar-like structures with a diameter of ~12 nm (top) and vesicular-like structures of variable sizes 
(bottom) were identified. 
 
 
500 nm 500 nm
Results 
 
58 
 
3.  Cellular localization of proteins identified by proteomics 
In order to clarify the subcellular localization of the proteins found in 630 
culture supernatants, we selected three proteins representing different classes and 
analyzed their presence in culture supernatants and in cellular fractions (Fig. 6). 
Antibodies against recombinant CD630_01830 (MW: 37 kDa), CD630_23650 
(MW: 39kDa) and CD630_02370 (FliD, MW: 58 kDa) proteins were generated 
in mice. 630 cell and supernatant fractions were then analyzed by 
immunoblotting.  
Presence in culture supernatants was confirmed for all three proteins. 
Particularly, CD630_01830 and CD630_23650 were found in the supernatant 
both before and after ultracentrifugation but were absent in the pellet, indicating 
that these proteins were not derived from any membranous or cell wall fragments 
released from the cells. On the contrary, FliD was also found in the 
ultracentrifugation pellet, supporting the hypothesis that entire flagellar structures 
may be released into the media (Fig. 5 and 6). 
In accordance to the predicted association to the cell wall, CD630_01830 and 
CD630_23650 proteins were found in the fractions containing cell-wall 
associated proteins (ME and SL). On the contrary, the flagellar cap protein FliD 
was largely found as expected only in the protoplast cell fraction (Fig. 6). 
To understand if these proteins were immunogenic in mice, recombinant proteins 
were probed by immunoblotting with anti-sera raised against concentrated 
supernatants (Fig. 7). In this analysis, in addition to the proteins described above, 
we included five additional recombinant proteins, namely CD630_14690 (MW 
77 kDa), CD630_27950 (MW 59 kDa), CD630_05140 (MW 123 kDa), 
CD630_21770 (MW: 29 kDa) and CD630_36690 (MW: 21kDa). We observed 
bands of the predicted molecular weights for all the proteins tested, indicating 
that all of them were present in the supernatants and were immunogenic (Fig. 
7B). 
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Thus our data confirm that surface-associated proteins are present in the C. 
difficile culture supernatants and at least some of these are immunogenic in mice.  
 
 
 
 
Figure 6. Cellular localization of C. difficile 630 proteins detected by LC-MS/MS. Immunoblotting 
analysis of cell and supernatant fractions prepared from exponential phase cultures with antisera 
generated against CD630_01830, CD630_23650 and CD630_02370 (FliD). Cell fractions: total extract 
(TE), protoplast (P), mutanolysin extract (ME), S-layer extract (SL). Supernatant fractions: total 
supernatant (TS), supernatant after ultracentrifugation (US), ultracentrifugation pellet (UP). 10 ng of each 
recombinant protein (RP) were loaded as control. 
 
 
 
 
 
Figure 7. Immunoblotting on C. difficile 630 proteins detected by LC/MS/MS using an anti-
supernatant antibody. (A) Generation of a serum raised against culture supernatants by immunization of 
mice with concentrated supernatants from exponentially grown bacteria. (B) Immunoblotting analysis of 
recombinant proteins (CD630_01830, CD630_02370, CD630_14690, CD630_21770, CD630_23650, 
CD630_27950, CD630_36690 and CD630_05140) with anti-supernatant serum. 
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4. Selection of proteins potentially involved in C. difficile pathogenesis for 
functional characterization 
After a subset of C. difficile surface/released proteins was identified, we 
focused our attention on proteins annotated as “hypothetical”, for which a 
putative function has not been hypothesized. 6 hypothetical proteins were 
identified (Table 2 and 3). 4 of them were detected in both 630 and R20291, 
while CD630_21270 and CD630_11560 were detected only in 630 supernatants. 
We took advantage of basic bioinformatics methods to identify, through analysis 
of the amino acid sequences of these proteins, conserved domains which could 
suggest a function (Table 5).  
CD630_05490 was found to contain a formin homology 2 domain (pfam02181), 
found in proteins involved in actin polymerization. CD630_11560 contains a 
domain belonging to the transglutaminase-like superfamily (pfam01841); 
bacterial proteins containing domains of this family have been proposed to act as 
proteases (Makarova et al., 1999). For 2 proteins, CD630_21270 and 
CD630_2251, no conserved domains could be identified. A blastp search of 
CD630_28300 (against all the proteins in the NCBI database) revealed similarity 
to sequences containing an Anthrax Toxin Lethal Factor domain (ATLF, 
pfam07737). This is the catalytic domain of Bacillus anthracis major toxin 
Lethal Factor (Tonello and Montecucco, 2009). CD630_36690 contains at the C-
terminus a GERMN domain (pfam10646). GerMN is a region of approximately 
100 residues that is found in a number of different species of sporulating and 
non-sporulating bacteria, both alone and in association with other domains 
(Rigden and Galperin, 2008). Bacillus subtilis protein GerM, in which two copies 
of GerMN domain are present, has been implicated in both sporulation and spore 
germination (Sammons et al., 1987; Slynn et al., 1994). Based on these analysis, 
we decided to focus our attention on further characterization of CD630_28300 
and CD630_36690. 
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CD630_28300 protein was detected in both 630 and R20291 (CDR20291_2721) 
culture media and its amino acid sequence is conserved among the C. difficile 
genomes filed in the NCBI database with an aminoacid identity ranging from 98 
to 100% (it is present in 18 out of 20 genomes, the two remaining genomes being 
reported as “draft assemblies”). The presence of CD630_28300 in supernatants 
could not be confirmed by immunoblotting. As mice serum raised against the 
recombinant protein was not able to recognize it, the recombinant form of this 
protein is probably poorly immunogenic. This hypothesis is supported also by the 
inability of the serum raised against the concentrated supernatant to recognize the 
recombinant protein (data not shown). 
Blastp searches of the NCBI database using the CD630_36690 amino acid 
sequence as the query against each of 20 C. difficile strains reported in the 
database showed that this protein is conserved in 18 out of 20 C. difficile strains, 
with a percentage of identity ranging from 96% to 100% (the two remaining 
genomes being reported as “draft assemblies”). The presence of this protein in 
culture supernatant was confirmed by immunoblotting (Fig. 7B). At the N-
terminus of CD630_36690 a signal peptide is predicted (SignalP). Also, analysis 
with PROSITE revealed the presence of a putative Prokaryotic lipoprotein motif 
(PS51257).  
 
 
 
 
Table 5. Conserved domains identified by in silico analysis of the hypothetical proteins detected in 
630 and R20291 supernatants. 
 
Hypthetical protein Result of in silico analysis
CD630_05490 formin homology 2 domain
CD630_11560 transglutaminase-like superfamily
CD630_21270 no conserved domains
CD630_22510 no conserved domains
CD630_28300 similarity to Anthrax Lethal Factor catalytic domain
CD630_36690 GerMN domain
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5. CD630_28300 is a novel protease displaying zinc-dependent activity on 
the extracellular matrix protein fibronectin 
5.1. CD630_28300 shares similarity to the Anthrax Lethal Factor 
Alignment of the ATLF domain of CD630_28300 to the C-terminal, 
catalytically active, ATLF domain of Anthrax Lethal Factor (LF) of Bacillus 
anthracis showed that the two sequences share an amino acid identity of 22% 
and that residues mainly involved in proteolytic activity for LF and other zinc 
proteases are conserved, including the HEXXH motif (Fig 8). 
 
 
 
 
 
 
Figure 8. CD630_28300 shares sequence similarity with the C-terminal ATLF catalytic domain of 
Anthrax Lethal Factor (LF). Residues previously involved in the proteolytic activity in B. anthracis and 
other zinc metallopeptidases (indicated in red) are conserved. SP, signal peptide. 
 
 
 
 
5.2. Preparation of recombinant CD630_28300 for activity assays 
Given similarity with anthrax LF and conservation of catalytic residues, we 
decided to investigate proteolytic activity of CD630_28300. For this purpose, we 
expressed and purified a 6His-tagged recombinant protein. As the His tag is able 
to interact with divalent cations and could interfere with CD630_28300 metal 
binding ability and proteolytic activity, we decided to generate a tag-less protein 
using a two-step purification protocol, as described in Methods. In order to study 
SP ATLF superfamily Anthrax-tox_M superfamily ATLF superfamily
SP ATLF superfamily
1 22026
CD630_28300
LF
LF ATLF                 -DTKIQEAQLNINQEWNKALGLPKYTKLITFNVHNRYASNIVESAYLILNEWKNNIQSDLIKKVTNYLVDGNGRF
CD630_28300 ATLF        DSTTIQQNKDTLSQIVVFPTGN--YDKNEANAMVNRLAN--IDGKYLNALK-QNNLK---IKLLSGKLTDEK-EY
.*.**: : .:.*    . *   * *  :  : ** *.  ::. **   : :**::   ** ::. *.* : .:
LF ATLF                 VFTDITLPNIAEQYTHQDEIYEQVHSKGLYVPESRSILLHGPSKGVELRNDSEGFIHEFGHAVDDYAGYLLDKNQ
CD630_28300 ATLF        AYLKGVVP---KGWEGTGKTWDDVPGLGGSTVALR-IGFSNKGKGHDAIN---LELHETAHAIDHIV--------
.: . .:*   : :   .: :::* . *  .   * * : . .** :  *     :** .**:*. . 
LF ATLF                 SDLVTNSKKFIDIFKEEGSNLT—-SYGRTNEAEFFAEAFRLMHSTDHAERLKVQKNAPKTFQFINDQIKFIINS
CD630_28300 ATLF        LNDISKSAQFKQIFAKEGRSLGNVNYLGVYPEEFFAESFAYYYLNQDTN-SKLKSACPQTYSFLQNLAK-----
: :::* :* :** :** .*   .* . *****:*   : .:.::  *::. .*:*:.*:::  *
                                                                                                                          Results 
 
63 
 
functionality of the protein in the absence of metals or in presence of different 
metals, treatment with a chelating agent (EDTA) was carried out, eventually 
followed by incubation with ZnCl2, CuCl2 or NiCl2. 
 
5.3. CD630_28300 is a novel zinc-metalloprotease 
We tested catalytic activity of the recombinant protein on gelatin, a generic 
substrate commonly used to detect proteolytic activity, using a fluorimetric assay 
(Fig. 9). In this experiment, gelatin peptides are heavily labelled with both 
fluorescein (FITC) and a quenching agent. The enzymatic cleavage of the 
substrate molecule results in the separation of the quencher from the 
fluorochrome and consequently in an increase in fluorescence (that is 
proportional to the proteolytic activity). The experiment was carried out with the 
protein in the “apo” form or in presence of several divalent cations: Zn2+, Cu2+ 
and Ni
2+
. We could observe a weak, slow proteolytic activity in the presence of 
Zn
2+
, but not in the other conditions tested (Fig. 9). The weakness of the 
observed activity is not surprising, as we cannot rule out that the substrate and 
reaction conditions used are suboptimal for this protease. However, a clear 
proteolytic activity could be detected, interestingly only in the presence of zinc, 
as we could expect based on conservation of zinc-binding residues (Fig. 8). 
 
 
 
Figure 9. Proteolytic activity of CD630_28300 in a gelatinase/collagenase fluorimetric assay. 
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5.4. CD630_28300 displays a zinc-dependent cleavage of the extracellular 
matrix protein fibronectin 
As other bacterial metalloproteases have been previously reported to be able 
to degrade extracellular matrix (ECM) proteins (Molla et al., 1988; Teo et al., 
2003), we examined if CD630_28300 could cleave ECM components in vitro in 
the presence of Zn
2+
. We tested collagen types I, II, III, IV, V and VI and 
fibronectin. While none of the collagens was cleaved (data not shown), 
fibronectin was cleaved in a time-dependent manner (Fig. 10A). To rule out that 
the observed activity was unspecific, a similar reaction was carried out in the 
presence of an unrelated recombinant protein purified in a similar manner (Fig. 
10A). Testing CD630_28300 proteolytic activity in the absence of metals or in 
the presence of Cu
2+
 or Ni
2+
, we observed the highest activity in the presence of 
Zn
2+
, in accordance with the zinc-binding function previously reported for ATLF 
domain (Fig. 10B). These data demonstrate that CD630_28300, which we have 
named zinc metalloprotease 1 (Zmp1), is a novel C. difficile zinc-dependent 
protease with acivity on fibronectin.  
 
 
 
Figure 10. Zmp1 is a zinc-dependent protease with fibronectin-cleaving activity. (A) Time-dependent 
proteolytic activity of recombinant Zmp1 on fibronectin. 30 µg fibronectin from human plasma were 
incubated for 24 hours at 37°C with an equal amount of Zmp1 in the presence of 0.5 mM ZnCl2. At 0, 3, 
6, 12 and 24 hours after incubation, 1 µg of fibronectin was analyzed by SDS-PAGE followed by silver 
staining. Integrity of fibronectin in the absence of Zmp1 was verified after 0 and 24 h of incubation in the 
same conditions. (B) Zinc-dependent proteolytic activity of recombinant Zmp1 on fibronectin. 5 µg of 
fibronectin from human plasma were incubated for 24 h at 37°C with an equal amount of Zmp1 in the 
presence of 0.5 mM ZnCl2, NiCl2, CuCl2 or in the absence of divalent cations. 1 µg of fibronectin was 
analyzed by SDS-PAGE and silver staining. 
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5.5. Residues E143 and H146 are important for Zmp1 catalytic activity 
To further analyze the residues that are involved in Zmp1 catalytic activity, 
we generated mutants in the HEXXH motif, that is considered a fingerprint for 
zinc metalloproteases and has been characterized in anthrax LF as well as in 
other toxins, such as the tetanus and botulinum neurotoxins. In this motif, the 
imidazole rings of the two histidine residues have been identified as part of the 
first shell of zinc coordination, while the glutamate carboxylate binds the water 
molecule implicated in the hydrolytic reaction (Tonello and Montecucco, 2009). 
We generated by site-directed mutagenesis two mutants of Zmp1, E143A and 
H146A. Stability and zinc-binding ability of these mutants were evaluated by 
differential scanning fluorimetry (DSF) (Fig. 11A). In the DSF assay, both 
mutants showed a melting temperature comparable to the wild type, indicating 
that mutations do not affect protein stability. The E143A mutant was able to bind 
zinc, as demonstrated by an increase in melting temperature observed upon 
addition of this metal. On the contrary, in the H146A mutant the ability to bind 
zinc was completely lost (Fig. 11A). Both mutant proteins showed a reduced 
proteolytic activity on fibronectin in the presence of zinc, indicating that residues 
E143 and H146 are both important for the catalytic activity (Fig. 11B).  
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Figure 11. Decreased fibronectin-cleaving activity of E143A and H146A Zmp1 mutants. (A) 
Differential scanning fluorimetry of wild type, E143A and H146A recombinant proteins in the absence or 
presence of Zn
2+
. The minimum of the derivative is the melting temperature. Shifts in melting curves for 
the wild type and mutant proteins are indicated with arrows. (B) Decreased ability of E143A and H146A 
Zmp1 mutants to cleave fibronectin. 5 µg of fibronectin from human plasma were incubated for 24 h at 
37°C with no Zmp1 or with an equal amount of wild type (wt), E143A or H146A Zmp1 in the presence 
of 0.5 mM ZnCl2. 1 µg of fibronectin was analyzed by SDS-PAGE and silver staining. 
 
 
5.6. Zmp1 destabilizes the fibronectin network produced by human 
fibroblasts  
We examined if the ability to cleave fibronectin in vitro was relevant also in a 
cell model resembling the ECM components produced by host cells. We used a 
human fibroblast cell line (IMR-90) producing a complex fiber organization 
mainly composed of fibronectin and collagens. Upon incubation of the cells with 
wild type Zmp1, we found that the discrete fibronectin network observed in the 
untreated cells was destabilized (Fig. 12); particularly, we observed the 
appearance of unstructured fibers of cellular fibronectin indicative of proteolytic 
activity of the protein (inset in Fig. 12). This effect is zinc-dependent since the 
fiber disorganization is maximized by the addition of ZnCl2 in the culture, 
whereas a minor effect is observed in the absence of the cation in the medium 
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(data not shown). E143A and H146A mutations in Zmp1 abrogate the observed 
destabilization of the fibronectin network (Fig. 12). 
These data suggest that Zmp1 is able to cleave native fibronectin and may 
indicate a potential role for this enzyme during C. difficile colonization of the gut 
and dissemination. 
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Figure 12. Proteolytic activity of Zmp1 protein on native fibronectin produced by cultured human 
fibroblasts. IMR-90 human fibroblasts were incubated with 250 μg/ml of wild type, E143A or H146A 
Zmp1 protein for 16 h as described in Methods. Fibronectin was labeled using a specific antibody 
followed by Alexa568-conjugated secondary antibodies (red) and nuclei were stained with DAPI (blue). 
Control cells were incubated with an equivalent volume of buffer for the same time period. 
Destabilization of fibronectin was observed upon treatment of cells with Zmp1, as also highlighted in the 
inset.  
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6. CD630_36690 is a surface protein with a potential role in C. difficile 
spores 
6.1. CD630_36690 contains a C-terminal GerMN domain 
CD630_36690 has a predicted amino acid sequence of 191 amino acids (Fig. 
13). At the N-terminus a signal peptide is predicted (SignalP). Also, analysis of 
CD630_3669 with PROSITE revealed a Prokaryotic lipoprotein motif 
(PS51257). Searching for conserved domains on NCBI, a GERMN domain 
(pfam10646), a widespread domain previously implicated in sporulation and 
germination in B. subtilis GerM, was identified at the C-terminus (amino acids 
74-181) (Rigden and Galperin, 2008; Slynn et al., 2004) (Fig. 13). GerMN 
domain, which is often found associated to other domains or in two copies (as is 
the case of GerM protein) (Rigden and Galperin, 2008), is found alone in 
CD630_36690 (Fig. 13). 
 
 
 
 
 
 
Figure 13. CD630_36690 contains a C-terminal GerMN domain. (A) Schematic representation of C. 
difficile CD630_36690 and Bacillus subtilis GerM proteins. (B) Alignment of the first GerMN domain of 
GerM with the GerMN domain of CD630_36690. SP, signal peptide. 
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6.2. Generation of a 630/ΔCD630_36690 deletion mutant 
To investigate the function of CD630_36690, a deletion mutant was 
generated in strain 630, taking advantage of an allele exchange strategy set up by 
Cartman and co-workers (Cartman et al., 2012). 
A suitable construct was generated cloning “in frame”, in the pMTL-SC7315 
vector (Cartman et al., 2012), the two regions flanking the gene of interest, in 
order to substitute the functional endogenous gene with a short sequence coding 
for a non-functional short peptide. The construct was transformed in C. difficile, 
where two steps of selection where carried out, as described in Methods. First, 
clones which had integrated the entire plasmid were selected for antibiotic 
resistance and checked by PCR (data not shown); then, clones which had 
undergone excision of the plasmid (resulting either in deletion of the gene or in 
recovery of the wild type genotype) were positively selected on fluorocytosin and 
the genotype (wild type or deletion mutant) was determined by PCR (Fig. 14). 
 
 
 
 
 
Figure 14. PCR selection of 630/ΔCD630_36690 deletion mutant. PCR was carried out on DNA 
extracts of fluorocytosine-positive clones. Primers external to the CD630_36690 coding sequence were 
used. Expected molecular weight is 1795 bp for the wild type, 1240 bp for the deletion mutant. 
 
 
 
 
6.3. CD630_36690 is expressed on the surface of vegetative cells 
Subcellular localization of CD630_36690 was carried out by immunoblotting 
and immunofluorescence analysis. Immunoblotting was performed on bacterial 
fractions prepared from a 630 culture collected in exponential phase, using an 
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antibody raised against the recombinant protein. Protoplast, cell wall and S-layer 
fractions of 630 and 630/ΔCD630_36690 were analyzed. CD630_36690 was 
mainly detected in the cell wall fraction, which contains proteins associated to 
the peptidoglycan as well as proteins associated to the S-layer. At least two bands 
of approximately 20 kDa can be observed. These bands may correspond to 
different maturation forms of a lipoprotein. A band of approximately 14 kDa, 
which can be observed only in the cell wall fraction, may correspond to a 
degradation product. All the bands detected are specific, as none of them can be 
observed in fractions of the deletion mutant prepared with the same procedure 
(Fig. 15A). Immunofluorescence analysis carried out on 630 and 
630/ΔCD630_36690 vegetative cells collected in late exponential phase 
confirmed that CD630_36690 is expressed on the surface of vegetative cells (Fig. 
15B). 
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Figure 15. CD630_36690 is expressed on the surface of 630 vegetative cells. (A) Immunoblotting 
analysis of cell fractions from 630 (WT) and 630/ΔCD630_36690 (ko) using an anti-CD630_36690 
specific antibody. Cell fractions: total extract, protoplast, cell wall (mutanolysin extract), S-layer extract. 
10 ng of recombinant protein were loaded as a control. (B) Immunofluorescence analysis of 
630/ΔCD630_36690 (left) and 630 (right) vegetative cells. CD630_36690 was labeled using a specific 
antibody followed by Alexa568-conjugated secondary antibody (red). Nuclei were stained with DAPI 
(blue). 
 
 
 
6.4. CD630_36690 has a potential role in C. difficile spore 
To characterize the deletion mutant, first we compared growth in rich medium 
with respect to the wild type. 630/ΔCD630_36690 did not show any growth 
defect up to the stationary phase (Fig. 16A). On the contrary, after reaching the 
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stationary phase, the mutant strain showed a decrease in optical density faster 
than the wild type, which could suggest a faster bacterial death (Fig. 16B). 
Given the previous association of GerMN domain with sporulation and 
germination (Sammons et al., 1987; Slynn et al., 1994), we wanted to assess the 
involvement of CD630_36690 in these processes. For this purpose, we 
performed vital counts of ethanol-resistant colonies of 630 and 
630/ΔCD630_36690 at different times of the growth curve (Fig. 16C and D). 
When C. difficile cultures are treated with ethanol, only spores are able to survive 
while vegetative cells are killed (Borriello and Honour, 1981). Plated on the 
germination inducer taurocholate, these spores produce colonies. The number of 
colonies is a result of several factors: (i) the number of spores that are present in 
the original culture, (ii) the ability of spores to survive ethanol treatment, (iii) the 
ability of spores to germinate on taurocholate and (iv) the ability of germinated 
spores to moltiplicate and form a visible colony. 630/∆CD36690 showed a 
reduced ability to form ethanol resistant colonies compared to 630 at different 
times of growth (5 and 24 h) (Fig. 16D). The mutant did not show any defect in 
the number of vital vegetative cells (Fig. 16C), indicating that the observed 
phenotype is not due to a lower number of vegetative cells in the culture. Also, 
we can exclude a defect in multiplication, as mutant colonies had the same size 
of wild type colonies (data not shown). Therefore, it is likely that this gene has a 
role in sporulation (affecting the number of spores produced or their resistance to 
ethanol treatment) or in germination. 
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Figure 16. 630/ΔCD630_36690 has a reduced ability to form ethanol-resistant colonies with respect 
to 630. (A) and (B) 630/ΔCD630_36690 growth is comparable to 630 up to the exponential phase (A), 
but undergoes a faster decrease in optical density after reaching the stationary phase (B). (C) Vital counts 
of 630 and 630/ΔCD630_36690 vegetative cells at 3 hours (mid exponential phase) and 24 hours (death 
phase). Diluted cultures were plated on taurocholate. (D) Vital counts of ethanol-resistant colonies at 5 
hours and 24 hours (earlier points were not evaluated because of the low number of spores produced). 
Following ethanol treatment, cultures were diluted and plated on taurocholate. All experiments were 
performed in triplicate.  
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DISCUSSION 
 
 
Although extracellular proteins are known to mediate events involved in the 
gut pathogenesis during C. difficile infections, not many cell surface or secreted 
proteins of the nosocomial pathogen C. difficile have been identified or 
functionally characterized.  
Previous studies tried to globally characterize extracellular protein profiles of this 
pathogen, but a certain percentage of bacterial lysis, leading to contamination of 
extracellular proteins preparations with cytoplasmic proteins, did not allow 
assignment of the identified proteins to their correct subcellular compartment 
(Boetzkes et al., 2012; Wright et al., 2005; Mukherjee et al., 2002). Combining a 
protocol that minimizes contamination with cytoplasmic proteins and sensitive 
proteomic techniques, we were able to identify a subset of extracellular C. 
difficile proteins from two clinically relevant strains. 
Interestingly, we found that the culture supernatant comprises largely of surface-
associated proteins. This was recently reported also by Boetzkes et al., who could 
identify the presence of several putative surface-associated proteins in culture 
filtrates, however along with the presence of a large number of cytoplasmic 
proteins (Boetzkes et al., 2012). The presence of cytoplasmic proteins, which is a 
common indicator of lysis, is found in several proteomic studies examining the 
exoproteomes and complicates the interpretation of the cellular localization of 
proteins (Pacheco et al., 2011; Sengupta et al., 2010). Our work suggests that the 
proteins we detected in culture supernatants are indeed extracellular, as the 
preparations we used almost completely lacked proteins of predicted cytoplasmic 
origin. Among the proteins we detected in supernatants, the Cwp84 cysteine 
protease and SlpA, the precursor of the two major S-layer proteins, have been 
well studied and previously reported to be present in culture supernatants (de la 
Riva et al., 2011). The largest known CWP, CwpV, which promotes C. difficile 
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aggregation, was also detected (Reynolds et al., 2011). Several proteins that we 
found, such as Cwp84, SlpA, FliC, FliD, Cwp2, Cwp18, Cwp66, CD630_26720 
and CD630_08730, have been shown to be immunoreactive to human sera 
(Pechine et al., 2005; Wright et al., 2008). In addition to known proteins, many 
other uncharacterized CWPs, hydrolases, transporters and hypothetical proteins 
are reported in this study. Further characterization of these proteins could provide 
insight into both bacterial physiology and pathogenesis. 
Based on our observations, most surface-proteins identified appear to be released 
as single proteins and not in association to macromolecular structures (i.e. 
membrane vesicles or cell wall fragments). The only structure that seems to be 
released as a whole unit is the flagellum. Surface proteins have been reported 
from culture supernatants of other Gram-positive bacteria (Desvaux et al., 2010; 
Ravipaty and Reilly, 2010). The cleavage of surface proteins by proteases has 
been previously proposed as a mechanism by which proteins are released from 
the surface in bacteria such as Streptococcus pyogenes (Nelson et al., 2011). The 
mechanisms controlling the release of surface associated proteins in C. difficile 
are at present unclear. C. difficile encodes at least two cysteine proteases, Cwp84 
and Cwp13, which are involved in surface maturation (Kirby et al., 2009; Dang 
et al., 2010; de la Riva et al., 2011). A possibility is that these, other reported or 
yet unidentified proteases are involved in cleavage of some surface proteins of C. 
difficile. Indeed, surface proteins may be released or shed into the extracellular 
environment, perhaps as a result of abundant expression on the surface. Presence 
of surface-associated proteins in the extracellular milieu may suggest that in vivo, 
during infection, such proteins are not just associated to the bacterial surface but 
may also act distally.  
Preliminary analyses on the mechanisms involved in release of surface proteins 
led us to the observation of membrane vesicles in culture supernatants. Although 
we did not go into the characterization of these structures, this is an interesting 
observation, as such structures were never observed before in clostridial 
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supernatants. A variety of Gram-negative pathogenic or environmental bacteria 
secrete outer membrane vesicles (OMVs), which are produced during normal 
bacterial growth (Ellis & Kuehn, 2010). These are spherical nanovesicles that 
have been demonstrated to contain virulence factors in several pathogenic 
species, like Escherichia coli and Pseudomonas aeruginosa (Wai et al., 2003; 
Kesty & Kuehn, 2004; Bomberger et al., 2009), and their contribution to 
bacterial pathogenesis has been characterized. In contrast, little is known about 
such processes in Gram-positive bacteria. Membrane vesicles production has 
been reported in Staphilococcus aureus (Gurung et al., 2011; Lee et al., 2009; 
Hong et al., 2011), Bacillus subtilis (Dorward and Garon, 1990), Bacillus cereus 
(Dorward and Garon, 1990) and Bacillus anthracis (Rivera et al., 2010). 
Interestingly, vesicles of B. anthracis have been involved in secretion and 
targeting of the anthrax major toxins (Rivera et al., 2010). It is still unclear the 
mechanism by which C. difficile toxin A and toxin B are secreted. It has been 
proposed that these huge toxins are released through the product of the tcdE 
gene, present within the pathogenicity locus, which presents sequence and 
structure similarities to bacteriophage-encoded holins. However, it has recently 
been demonstrated that TcdE does not exhibit pore-forming function in C. 
difficile (Olling et al., 2012). It would be interesting to study if C. difficile 
vesicles contain toxins and have a role in their targeting, as it has been shown for 
B. anthracis. 
The global analysis of C. difficile supernatants resulted in the identification of six 
unknown hypothetical proteins. Based on similarities to known domains or 
proteins, we found some proteins that may be involved in clostridial 
pathogenesis. One of such proteins is the zinc-dependent metalloprotease Zmp1. 
We demonstrated that Zmp1 can degrade fibronectin not only in vitro, but also 
on cultured human fibroblasts that produce a dense fibronectin network. By 
selectively mutating residues that are in the HEXXH motif, a conserved motif 
typical to zinc metalloproteases and crucial for proteolytic activity (Klimpel et 
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al., 1994), we showed that specific residues E143 and H146 are crucial for the 
catalytic activity of Zmp1. DSF analysis showed that H146 is required for 
binding to Zn
2+
, while both the residues are key for activity on purified 
fibronectin in vitro. This is in accordance with the role previously attributed to 
these residues in other zinc metalloproteases (Klimpel et al., 1994; Teo et al., 
2003). Our in vitro studies showed that Zmp1 is active on fibronectin, but not on 
any of the collagen types that were tested. Moreover, a weak activity on gelatin 
could be detected by FRET. Thus, although Zmp1 does not demonstrate a strong 
fibronectin cleaving activity in our in vitro conditions, it is evident that this 
activity is highly specific. It is likely that this enzyme has optimal activity on 
other biological substrates. Further studies with a wider collection of known 
biological substrates could shed light on alternate substrates of this novel 
metalloprotease. 
Proteolytic enzymes are frequently involved in the bacterial colonization process, 
contributing to nutrient acquisition, degradation of host proteins or processing of 
bacterial proteins involved in pathogenesis (Maeda, 1996). Previous studies 
showed that C. difficile displays a proteolytic activity correlated with strain 
virulence in the hamster model (Poilane et al., 1998; Seddon et al., 1990; Seddon 
and Borriello, 1992). However, few proteolytic factors of C. difficile have been 
characterized so far and the role of hydrolytic enzymes in C. difficile 
pathogenesis is still unclear. Fibronectin degrading enzymes have been 
previously implicated in bacterial virulence (Finkelstein et al., 1983; Guillemet et 
al., 2010). These enzymes have been shown to affect the ability to colonize in the 
gut, and hence to affect disease pathogenesis (Finkelstein et al., 1983). During 
pathogenesis of C. difficile, Zmp1 may aid the bacterial colonization processes in 
the gut by degrading ECM proteins associated with the gut epithelial cells. 
Indeed, this enzyme may have additional biological substrates that assist in gut 
penetration or nutrient acquisition. 
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Analysis of proteins of unknown function contained in culture supernatants 
revealed also the presence of a novel protein containing a GerMN domain, 
named CD630_36690 in strain 630. Genetic studies on the Bacillus subtilis 
GerM protein, which contains two copies of GerMN domain, have previously 
involved this domain in both sporulation and spore germination, suggesting an 
important role in cell development. However, the role and mechanism of action 
of GerM in these processes has not been characterized (Slynn et al., 1994; 
Sammons et al., 1987). Recently, a bioinformatic analysis was carried out to 
study the presence of the GerMN domain in several bacterial phyla (Rigden and 
Galperin, 2008). These searches revealed that the organization of this domain and 
its combination with other conserved domains is much variable and that the 
GerMN domain is conserved among both sporigenous and asporigenous bacterial 
species. These analyses led the authors to hypothesize that GerMN is a 
widespread cell development domain, whose function might involve binding to 
the peptidoglycan. We demonstrated that this protein is expressed on the surface 
of vegetative cells. Moreover, our preliminary genetic study, aimed at analyzing 
the involvement of CD630_36690 in C. difficile sporulation and germination, 
suggested that this factor is involved in one or both of these processes. Therefore 
we can hypothesize two scenarios: i) the protein is a sporulation and/or 
germination factor, directly involved in sporulation and/or germination; ii) the 
protein has a general role in cell development (for example in synthesis or 
degradation of peptidoglycan) and deletion of the encoding gene indirectly leads 
to a defect in sporulation or germination. Further studies are necessary to 
understand in which biological processes this protein is involved and if it has a 
role in pathogenesis. 
Thus, employing proteomics, we identified new extracellular factors that may be 
important for the pathogenesis of C. difficile. Further examination of the 
mechanisms involved in release of surface-associated proteins into the 
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extracellular milieu may shed light on how the clostridial cell surface may be 
modulated and how these proteins may interact with the host cells. 
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APPENDIX 1 – Growth media  
 
 
BHIS 
BHI 37 g/l 
Yeast extract 5 g/l 
L-cysteine 1 g/l 
ddH2O 
  
15 g/l agar are added to have a solid medium.  
The medium is sterilized in autoclave and stored at 4°C. 
 
 
TYM 
Tryptone peptone (Difco) 24 g/l 
Yeast extract                                                          12 g/l 
Mannitol                                                                   10 g/l 
Glycerol                                                                1 g/l 
ddH2O 
  
The pH is adjusted to 6.8. 
The medium is sterilized in autoclave and stored at 4°C. 
 
 
CDMM-Clostridium difficile Minimal medium 
Aminoacids: 
L-cysteine 0.5 g/l 
L-isoleucine                                                                          0.1 g/l 
L-leucine  1.0 g/l 
L-proline                                                                               0.8 g/l 
L-tryptophan  0.1 g/l 
L-valine 0.1 g/l 
L-arginine                                                                             0.1 g/l 
Glycine                                                                                 0.1 g/l 
L-histidine  0.1 g/l 
L-methionine                                                                        0.1 g/l 
L-threonine  0.1 g/l 
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Salts: 
KH2PO4 0.3 g/l 
Na2HPO4 1.5 g/l 
NaCl 0.9 g/l 
CaCl2∙2H2O 26 mg/l 
MgCl2∙6H2O 20 mg/l 
MnCl2∙4H2O 10 mg/l 
(NH4)2SO4 0.44 g/l 
FeSO4∙7H2O 4 mg/l 
NaHCO3 5 g/l 
 
Vitamins: 
Biotin 10 µg/l 
Calcium pantothenate 1 mg/l 
Pyridoxine hydrochloride 100 µg/l 
 
Powders are dissolved in ddH2O. 
The pH is adjusted to 7.4. 
The medium is filter sterilized and stored at 4°C. 
 
 
Minimal medium for selection of double cross-over clones (CDM) 
To make 100 ml Minimal medium: 
Sterile anaerobic ddH2O 61 ml 
Amino acid solution (5X) 20 ml 
Salt solution (10X) 10 ml 
20% glucose solution 5 ml 
Trace salt solution (50X) 2 ml 
FeSO4∙7H2O solution (100X) 1 ml 
Vitamin solution (100X) 1 ml 
 
Amino acid solution (5X): 
Dissolve the following quantities in 200 ml of ddH2O: 
Cas-amino acids 10.0 g 
L-Tryptophan 0.5 g 
L-Cysteine 0.5 g 
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Salt solution (10X): 
Dissolve the following quantities in 200 ml of ddH2O: 
KH2PO4 1.8 g 
NaCl 1.8 g 
Na2HPO4 10.0 g 
NaHCO3 10.0 g 
 
Glucose solution: 
20% w/v glucose 
 
Trace salt solution (50X): 
Dissolve the following quantities in 200 ml of ddH2O: 
CaCl2∙2H2O 260 mg 
MnCl2∙4H2O 100 mg 
MgCl2∙6H2O 200 mg 
(NH4)2SO4 400 mg 
 
FeSO4∙7H2O solution (100X): 
Dissolve 20 mg FeSO4∙7H2O in 50 ml anaerobic water 
 
Vitamin solution (100X): 
Dissolve each of the following vitamins in 200 ml of water: 
Ca-D-panthotenate 20 mg 
Pyridoxine 20 mg 
d-biotin 20 mg 
 
The medium is filter sterilized and stored at 4°C. 
 
 
LB 
Tryptone peptone 10 g/l 
Yeast extract 5 g/l 
NaCl 10 g/l 
dH2O 
  
The pH is adjusted to 7.6, then the medium is sterilized in autoclave and stored at 4°C. 
15 g/l agar are added to have a solid medium.  
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APPENDIX 2 - Oligonucleotides 
 
 
 
E143Af    GAATTACATGCAACAGCACATGCAATAGACC 
E143Ar    GTGCTGTTGCATGTAATTCTAAATTTATTGC 
H146Af    GAAACAGCAGCTGCAATAGACCATATAGTATTAAATGAT 
H146Ar    TATTGCAGCTGCTGTTTCATGTAATTCTAAATTTATTGC 
U3669f    TTTTTTGTTTAAACCGCTCTGTAGTATTAAATTATCAGTTATC 
U3669r    GGGCTAGAATTCCATAAAAATTTCTCCTCTCTTAAAAACTATTC 
D3669f    GGGCTAGAATTCGGAGATTACTTAAAGTAATTTCTTGAAACT 
D3669r    TTTTTTGTTTAAACCCAGGTATAGCAGGTCTTAACC 
int3669f  GCTTGATTCAGTTGCTCGTACTTAC 
int3669r  GAGCATTAGTACAACCAACTGCGAAT 
ext3669f  CATCTGCCATAGTTCTCCATTAAATCG 
ext3669r  GAAGGTGGAACAGGTAGTAAATCAG 
SC7-F     GACGGATTTCACATTTGCCGTTTTGTAAACGAATTGCAGG 
SC7-R     AGATCCTTTGATCTTTTCTACGGGGTCTGACGCTCAGTGG 
SC7-F1    GCCGTTTTGTAAACGAATTGCAGG 
SC7-R1    CTACGGGGTCTGACGCTC 
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